DrugRepV_2156 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (96.1181392 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2157 | Nitrofurazone | Blood and Blood Forming Organs; Dermatologicals; Dermatologicals; Antiparasitic products, Insectisid | Bacterial skin infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (92.2011022 %) | Approved | 27742486 |
DrugRepV_2158 | Tolfenamic Acid | Musculo-Skeletal System | Pain associated with the acute attack of migraines | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (91.0134313 %) | Approved, Investigational | 27742486 |
DrugRepV_2159 | Flunixin Meglumin | Anti-inflammatory | Anti-inflammatory agent (used in animals) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (57.8934305 %) | NA | 27742486 |
DrugRepV_2160 | Calcitriol | Alimentary Tract and Metabolism | Vitamin D deficiency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (57.47978 %) | Approved | 27742486 |
DrugRepV_2161 | Atovaquone | Antiparasitic products, Insectisides and Repellents | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (55.760271 %) | Approved | 27742486 |
DrugRepV_2162 | Epalrestat | Anti-diabetic | Diabetic neuropathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (54.8385744 %) | Investigational | 27742486 |
DrugRepV_2163 | Levosimendan | Cardiovascular agents | Chronic heart failure (CHF) | Heart disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (54.4775159 %) | Approved, Investigational | 27742486 |
DrugRepV_2164 | Menadione | Blood and Blood Forming Organs | Blood clotting | Bone calcification | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (54.2699321 %) | Approved, Nutraceutical | 27742486 |
DrugRepV_2165 | Repaglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (48.7632872 %) | Approved, Investigational | 27742486 |
DrugRepV_2166 | Azilsartan Medoxomil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (42.534615 %) | Approved | 27742486 |
DrugRepV_2167 | Diclofenac Diethylamine | Dermatologicals; Musculo-Skeletal System and Sensory Organ | Osteoarthritis and rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (40.6760631 %) | Approved | 27742486 |
DrugRepV_2168 | Nimesulide | Musculo-Skeletal System | Acute pain | Symptomatic treatment of osteoarthritis | Primary dysmenorrhoea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (39.2301835 %) | Approved, Investigational, Withdrawn | 27742486 |
DrugRepV_2169 | Acemetacin | Musculo-Skeletal System | Acute inflammation of the joints - Analgesic and antipyretic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (39.1366729 %) | Approved | 27742486 |
DrugRepV_2170 | Diclofenac Potassium | Dermatologicals; Musculo-Skeletal System and Sensory Organ | Fever and pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (38.1915639 %) | Approved | 27742486 |
DrugRepV_2171 | Lonidamine | Antineoplastic and Immunomodulating Agents | Benign prostatic hyperplasia | Prostate disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (35.3539647 %) | Investigational | 27742486 |
DrugRepV_2172 | Azilsartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (33.7555588 %) | Approved | 27742486 |
DrugRepV_2173 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (19.4231062 %) | Approved | 27742486 |
DrugRepV_2174 | Aprepitant | Alimentary Tract and Metabolism | Nausea and vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (18.8613362 %) | Approved | 27742486 |
DrugRepV_2175 | Fluvastatin Sodium | Cardiovascular agents | Cardiovascular disease (Coronary heart disease (CHD)) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (18.5093019 %) | Approved | 27742486 |
DrugRepV_2176 | Pizotifen Malate | Nervous System | Migraines | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (16.7563948 %) | Approved | 27742486 |
DrugRepV_2177 | Avobenzone | NA | Sunburn | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (16.643533 %) | Approved | 27742486 |
DrugRepV_2178 | Mitoxantrone Hydrochloride | Antineoplastic and Immunomodulating Agents | Multiple sclerosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (15.1626877 %) | Approved, Investigational | 27742486 |
DrugRepV_2179 | Irinotecan Hydrochloride Trihydrate | Antineoplastic and Immunomodulating Agents | Colorectal cancer | Small cell lung cancer | Cervical cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.6383286 %) | Approved, Investigational | 27742486 |
DrugRepV_2180 | Azelastine Hydrochloride | Respiratory System | Rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.2513127 %) | Approved | 27742486 |
DrugRepV_2181 | Lovastatin | Cardiovascular agents | Atherosclerotic vascular disease | Hypercholesterolemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.1848079 %) | Approved, Investigational | 27742486 |
DrugRepV_2182 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Ovulatory Dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.0147255 %) | Approved | 27742486 |
DrugRepV_2183 | Oxfendazole | Antiparasitic | Protects livestock from roundworm. strongyles, and pinworn | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (13.9350528 %) | Approved | 27742486 |
DrugRepV_2184 | Estradiol Valerate | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (13.5411627 %) | Approved | 27742486 |
DrugRepV_2185 | Etidronate | Musculo-Skeletal System | Paget disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (13.5390608 %) | Approved | 27742486 |
DrugRepV_2186 | Abiraterone | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (12.7697585 %) | Approved | 27742486 |
DrugRepV_2187 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (12.5546344 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2188 | Methylprednisolone | Dermatologicals; Dermatologicals; Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (11.8062257 %) | Approved, Vet approved | 27742486 |
DrugRepV_2189 | Scopolamine Hydrobromide | Alimentary Tract And Metabolism; Nervous System; Sensory Organ | Irritable bowel syndrome | Excessive salivation | Motion sickness | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (11.8009385 %) | Approved, Investigational | 27742486 |
DrugRepV_2190 | Neostigmine Bromide | Nervous System | Myasthenia gravis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (11.3329876 %) | Approved | 27742486 |
DrugRepV_2191 | L-Thyroxine | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Hypothyroidism | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.9745889 %) | Approved | 27742486 |
DrugRepV_2192 | Ziprasidone Hydrochloride | Nervous System | Schizophrenia and psychotic disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.899998 %) | Approved | 27742486 |
DrugRepV_2193 | Fenofibrate | Cardiovascular agents | Hypercholesterolemia | Dyslipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.8996039 %) | Approved | 27742486 |
DrugRepV_2194 | Nateglinide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.5810833 %) | Approved, Investigational | 27742486 |
DrugRepV_2195 | Fluoxetine Hydrochloride | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.4504102 %) | Approved, Vet approved | 27742486 |
DrugRepV_2196 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.2727802 %) | Approved | 27742486 |
DrugRepV_2197 | Olanzapine | Nervous System | Schizophrenia | Bipolar I disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.0723372 %) | Approved, Investigational | 27742486 |
DrugRepV_2198 | Neomycin Sulfate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (10.0220837 %) | Approved | 27742486 |
DrugRepV_2199 | Brompheniramine | Respiratory System | Allergies, rhinitis and urticaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (9.75770133 %) | Approved | 27742486 |
DrugRepV_2200 | Rifampin | Antiinfectives For Systemic Use | Tuberculosis and Tuberculosis-related mycobacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (9.11795232 %) | Approved | 27742486 |
DrugRepV_2201 | Atazanavir Sulfate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.91119067 %) | Approved | 27742486 |
DrugRepV_2202 | Miconazole Nitrate | Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective | Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.84799674 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2203 | Vorinostat | Antineoplastic and Immunomodulating Agents | T-cell lymphoma (CTCL, a type of cancer) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.83658563 %) | Approved | 27742486 |
DrugRepV_2204 | Dimethyl Fumarate | Anti-inflammatory | Multiple sclerosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.81629076 %) | Approved | 27742486 |
DrugRepV_2205 | Tiopronin | Genito Urinary System and Sex Hormones | Kidney stone | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.70633878 %) | Approved | 27742486 |
DrugRepV_2206 | Dutasteride | Genito Urinary System and Sex Hormones | Prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.1427081 %) | Approved | 27742486 |
DrugRepV_2207 | Ritodrine Hydrochloride | Genito Urinary System and Sex Hormones | Premature labour | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (8.00664706 %) | Approved, Investigational | 27742486 |
DrugRepV_2208 | Dipyridamole | Blood and Blood Forming Organs | Coagulation disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.91414617 %) | Approved | 27742486 |
DrugRepV_2209 | Proparacaine Hydrochloride | Sensory Organ | Ophthalmic anesthetic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.83586814 %) | Approved, Vet approved | 27742486 |
DrugRepV_2210 | Pefloxacin Mesylate | Antiinfectives For Systemic Use | Gonococcal urethritis in males | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.83586814 %) | Approved | 27742486 |
DrugRepV_2211 | Ranolazine Dihydrochloride | Cardiovascular agents | Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.80000539 %) | Approved | 27742486 |
DrugRepV_2212 | Butenafine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.76085859 %) | Approved | 27742486 |
DrugRepV_2213 | Diphenhydramine Hydrochloride | Dermatologicals and Respiratory System | Vertigo/Meniere disease, nausea and vomiting, motion sickness and insect bite | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.67086 %) | Approved | 27742486 |
DrugRepV_2214 | Moroxydine | Antiinfectives For Systemic Use | Influenza | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.65475751 %) | Experimental | 27742486 |
DrugRepV_2215 | Fudosteine | NA | Bronchial asthma | Chronic bronchitis | Pulmonary emphysema | Bronchiectasis | Pulmonary tuberculosis | Pneumoconiosis | Atypical mycobacterial disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.62256156 %) | NA | 27742486 |
DrugRepV_2216 | Pranlukast | Respiratory System | Allergic reaction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.56691777 %) | Approved | 27742486 |
DrugRepV_2217 | Etodolac | Musculo-Skeletal System | Osteoarthritis and rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.54969898 %) | Approved | 27742486 |
DrugRepV_2218 | Trifluridine | Sensory Organ | Primary keratoconjunctivitis and Herpes simplex keratitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.43774052 %) | Approved | 27742486 |
DrugRepV_2219 | Oxymetazoline Hydrochloride | Sensory Organ | Eye irritation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.399478 %) | Approved, Investigational | 27742486 |
DrugRepV_2220 | Tylosin tartrate | NA | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.36358127 %) | Vet Approved | 27742486 |
DrugRepV_2221 | Doxercalciferol | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Secondary hyperparathyroidism | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.31888883 %) | Approved | 27742486 |
DrugRepV_2222 | Fenoprofen Calcium | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.30740883 %) | Approved | 27742486 |
DrugRepV_2223 | Methoxsalen | Dermatologicals | Psoriasis | Vitiligo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.14420741 %) | Approved | 27742486 |
DrugRepV_2224 | Anastrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.12964085 %) | Approved | 27742486 |
DrugRepV_2225 | Ozagrel | Ophthalmic-agent | Dry eye syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.09023957 %) | Investigational | 27742486 |
DrugRepV_2226 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.05142618 %) | Approved, Investigational | 27742486 |
DrugRepV_2227 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.04365539 %) | Investigational | 27742486 |
DrugRepV_2228 | Fulvestrant | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.04032324 %) | Approved, Investigational | 27742486 |
DrugRepV_2229 | Clozapine | Nervous System | Psychosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.00172882 %) | Approved | 27742486 |
DrugRepV_2230 | Oxibendazole | Antiparasitic | Helminth intestinal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.98667471 %) | Investigational, Vet approved | 27742486 |
DrugRepV_2231 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.95397975 %) | Approved | 27742486 |
DrugRepV_2232 | Lapatinib Ditosylate | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.93254343 %) | Approved, Investigational | 27742486 |
DrugRepV_2233 | Reserpine | Cardiovascular agents | Hypertension | Psychotic disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.9045194 %) | Approved, Investigational | 27742486 |
DrugRepV_2234 | Rifaximin | Alimentary Tract and Metabolism | Traveller's Diarrhea | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.80622494 %) | Approved, Investigational | 27742486 |
DrugRepV_2235 | Arbidol Hydrochloride | NA | Influenza | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.59070859 %) | NA | 27742486 |
DrugRepV_2236 | Mianserin Hydrochloride | Nervous System | Depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.5508974 %) | Approved, Investigational | 27742486 |
DrugRepV_2237 | Terbinafine Hydrochloride | Dermatologicals | Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.51264741 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2238 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.50989786 %) | Approved | 27742486 |
DrugRepV_2239 | Acipimox | Cardiovascular agents | Hyperlipidemias | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.42097206 %) | Approved | 27742486 |
DrugRepV_2240 | Itraconazole | Antiinfectives For Systemic Use | Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.35827197 %) | Approved, Investigational | 27742486 |
DrugRepV_2241 | Novobiocin Sodium | NA | Staphylococci infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.24445866 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2242 | Asenapine | Nervous System | Psychosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.19909164 %) | Approved | 27742486 |
DrugRepV_2243 | 5-Aminolevulinic Acid Hydrochloride | Antineoplastic and Immunomodulating Agents | Actinic keratoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.19454622 %) | Approved | 27742486 |
DrugRepV_2244 | Azacyclonol | NA | Psychosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.14203789 %) | NA | 27742486 |
DrugRepV_2245 | Methenamine | Antiinfectives For Systemic Use | Urinary tract infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.11366498 %) | Approved, Vet approved | 27742486 |
DrugRepV_2246 | Azithromycin | Antiinfectives For Systemic Use | Microbial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.11366498 %) | Approved | 27742486 |
DrugRepV_2247 | Sunitinib Malate | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Gastrointestinal stromal tumor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.08231961 %) | Approved, Investigational | 27742486 |
DrugRepV_2248 | Tropicamide | Sensory Organ | Mydriasis and Cycloplegia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.04488039 %) | Approved | 27742486 |
DrugRepV_2249 | Praziquantel | Antiparasitic products, Insectisides and Repellents | Schistosomiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.93918289 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2250 | Celecoxib | Musculo-Skeletal System | Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.89285907 %) | Approved | 27742486 |
DrugRepV_2251 | Ibandronate Sodium | Musculo-Skeletal System | Osteoporosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.8438752 %) | Approved, Investigational | 27742486 |
DrugRepV_2252 | Phenytoin | Nervous System | Seizures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.83857713 %) | Approved, Vet approved | 27742486 |
DrugRepV_2253 | Beta-Carotene | Alimentary Tract And Metabolism; Dermatologicals | Nutrient supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.82798788 %) | Approved | 27742486 |
DrugRepV_2254 | Resveratrol | Anticancer | Herpes labialis infections (cold sores) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.82320541 %) | Approved, Experimental, Investigational | 27742486 |
DrugRepV_2255 | Deferasirox | Various | Tansfusional hemosiderosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.76811009 %) | Approved | 27742486 |
DrugRepV_2256 | Captopril | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.73529808 %) | Approved | 27742486 |
DrugRepV_2257 | Pyrimethamine | Antiparasitic products, Insectisides and Repellents | Toxoplasmosis | Acute malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.73171647 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2258 | Biapenem | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.72083061 %) | Investigational | 27742486 |
DrugRepV_2259 | Lidocaine | Cardiovascular agents | Anesthesia | Ventricular arrhythmias | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.70999199 %) | Approved, Vet approved | 27742486 |
DrugRepV_2260 | Calcium Levofolinate | Various | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.51423322 %) | NA | 27742486 |
DrugRepV_2261 | Azasetron Hydrochloride | NA | Nausea and vomiting induced by cancer chemotherapy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.49334625 %) | NA | 27742486 |
DrugRepV_2262 | Primidone | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.34861552 %) | Approved, Vet approved | 27742486 |
DrugRepV_2263 | Idoxuridine | Antiinfectives For Systemic Use | Keratoconjunctivitis and Keratitis caused by herpes simplex virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.28034643 %) | Approved, Investigational | 27742486 |
DrugRepV_2264 | Ellagic Acid | Antioxidant and Anti-proliferative | Follicular Lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.26155613 %) | Approved | 27742486 |
DrugRepV_2265 | Clindamycin Phosphate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.23907349 %) | Approved | 27742486 |
DrugRepV_2266 | Nisoldipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.19489422 %) | Approved | 27742486 |
DrugRepV_2267 | Conivaptan Hydrochloride | Cardiovascular agents | Hypervolemic hyponatremia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.13797577 %) | Approved | 27742486 |
DrugRepV_2268 | Pancuronium | Musculo-Skeletal System | Muscle relaxant during anesthesia and surgical procedures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.07557498 %) | Approved | 27742486 |
DrugRepV_2269 | Tigecycline | Antiinfectives For Systemic Use | Complicated skin and skin structure infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.03969688 %) | Approved | 27742486 |
DrugRepV_2270 | Trimebutine | Alimentary Tract and Metabolism | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.01937948 %) | Approved | 27742486 |
DrugRepV_2271 | Isotretinoin | Dermatologicals | Acne | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.00736344 %) | Approved | 27742486 |
DrugRepV_2272 | Flumazenil | Various | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.99459989 %) | Approved | 27742486 |
DrugRepV_2273 | Clobetasol Propionate | Dermatologicals | Psoriasis and dermatosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.9664796 %) | Approved | 27742486 |
DrugRepV_2274 | Roxatidine Acetate Hydrochloride | Alimentary Tract and Metabolism | Gastro-intestinal disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.9480885 %) | Experimental | 27742486 |
DrugRepV_2275 | Drospirenone | Genito Urinary System and Sex Hormones | Contraception | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.94004334 %) | Approved | 27742486 |
DrugRepV_2276 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.92265574 %) | Approved, Investigational | 27742486 |
DrugRepV_2277 | Econazole Nitrate | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.89847179 %) | Approved | 27742486 |
DrugRepV_2278 | Cisatracurium Besylate | Musculo-Skeletal System | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.8029401 %) | Approved | 27742486 |
DrugRepV_2279 | Cyproheptadine Hydrochloride | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.78644356 %) | Approved | 27742486 |
DrugRepV_2280 | OSI-420 | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.78127734 %) | NA | 27742486 |
DrugRepV_2281 | Antipyrine | Nervous System | Analgesic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.7739269 %) | Approved | 27742486 |
DrugRepV_2282 | Doripenem Hydrate | Antiinfectives For Systemic Use | Intra-abdominal infections and complicated urinary tract infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.71564204 %) | Approved | 27742486 |
DrugRepV_2283 | Sulfamethazine | Antiinfectives For Systemic Use | Bacterial infections (Bronchitis, prostatitis and urinary tract infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.70881807 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2284 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.70566399 %) | Approved | 27742486 |
DrugRepV_2285 | Aminoglutethimide | Antineoplastic and Immunomodulating Agents | Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast. | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.69804317 %) | Approved | 27742486 |
DrugRepV_2286 | Roflumilast | Respiratory System | Chronic Obstructive Pulmonary Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.69383115 %) | Approved | 27742486 |
DrugRepV_2287 | Iloperidone | Nervous System | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.68190957 %) | Approved | 27742486 |
DrugRepV_2288 | Erlotinib Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.66114654 %) | Approved | 27742486 |
DrugRepV_2289 | Minoxidil | Cardiovascular agents; Dermatologicals | Hypertension | Alopecia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.65421085 %) | Approved, Investigational | 27742486 |
DrugRepV_2290 | Ifosfamide | Antineoplastic and Immunomodulating Agents | Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.62298755 %) | Approved | 27742486 |
DrugRepV_2291 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.58224242 %) | Approved | 27742486 |
DrugRepV_2292 | Probucol | Cardiovascular agents | LDL and HDL cholesterol | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.54118117 %) | Approved, Investigational | 27742486 |
DrugRepV_2293 | Mepivacaine Hydrochloride | Nervous System | Analgesia | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.51844444 %) | Approved, Vet approved | 27742486 |
DrugRepV_2294 | Daidzein | NA | Dietary supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.45147852 %) | Experimental | 27742486 |
DrugRepV_2295 | Haloperidol | Nervous System | Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.44529073 %) | Approved | 27742486 |
DrugRepV_2296 | Adenine Hydrochloride | NA | Nutritional supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.42334798 %) | Approved | 27742486 |
DrugRepV_2297 | Tianeptine Sodium | Nervous System | Depressive disorder | Irritable bowel syndrome (IBS) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.41872904 %) | Investigational | 27742486 |
DrugRepV_2298 | Thioguanine | Antineoplastic and Immunomodulating Agents | Acute leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.41764454 %) | Approved | 27742486 |
DrugRepV_2299 | Sulfapyridine | Antiinfectives For Systemic Use | Dermatitis herpetiformis | Benign mucous membrane pemphigoid | Pyoderma gangrenosum | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.40977237 %) | Approved | 27742486 |
DrugRepV_2300 | Lubiprostone | Alimentary Tract and Metabolism | Constipation | Irritable bowel syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.40977237 %) | Approved, Investigational | 27742486 |
DrugRepV_2301 | Thiamphenicol | Antiinfectives For Systemic Use | Infectious diseases in cattle, pigs and poultry) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.40312446 %) | Experimental, Investigational | 27742486 |
DrugRepV_2302 | Tropisetron | Alimentary Tract and Metabolism | Nausea and vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.39903618 %) | Approved | 27742486 |
DrugRepV_2303 | Aniracetam | Nervous System | Psychosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.38872845 %) | Experimental | 27742486 |
DrugRepV_2304 | Levamisole Hydrochloride | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.33501607 %) | Approved, Investigational, Vet approved, Withdrawn | 27742486 |
DrugRepV_2305 | Sotalol | Cardiovascular agents | Atrial flutter | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.33498865 %) | Approved | 27742486 |
DrugRepV_2306 | Pemetrexed | Antineoplastic and Immunomodulating Agents | Cancer (Chemotherapy drug) | Malignant pleural mesothelioma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.33026007 %) | Approved, Investigational | 27742486 |
DrugRepV_2307 | Loratadine | Respiratory System | Rhinitis | Urticaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.27362909 %) | Approved, Investigational | 27742486 |
DrugRepV_2308 | Urapidil Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.25520328 %) | Investigational | 27742486 |
DrugRepV_2309 | Vinpocetine | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.10031537 %) | Investigational | 27742486 |
DrugRepV_2310 | Sulfamethizole | Antiinfectives For Systemic Use | Urinary tract infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.08218845 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2311 | Inulin | Various | Diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.04438602 %) | Approved, Investigational, Nutraceutical | 27742486 |
DrugRepV_2312 | Betamethasone Valerate | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Dermatoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.99594087 %) | Approved | 27742486 |
DrugRepV_2313 | Ritonavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.98622242 %) | Approved, Investigational | 27742486 |
DrugRepV_2314 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.96247894 %) | Approved | 27742486 |
DrugRepV_2315 | Memantine Hydrochloride | Nervous System | Alzheimer's dementia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.94665072 %) | Approved, Investigational | 27742486 |
DrugRepV_2316 | Etomidate | Nervous System | General anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.92770767 %) | Approved | 27742486 |
DrugRepV_2317 | Cytarabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.9061166 %) | Approved | 27742486 |
DrugRepV_2318 | Lenalidomide | Antineoplastic and Immunomodulating Agents | Multiple myeloma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.87586362 %) | Approved | 27742486 |
DrugRepV_2319 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.85778554 %) | Approved | 27742486 |
DrugRepV_2320 | Pioglitazone Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.84924548 %) | Approved, Investigational | 27742486 |
DrugRepV_2321 | Medroxyprogesterone Acetate | Genito Urinary System and Sex Hormones | Amenorrhea | Abnormal uterine bleeding | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.84716499 %) | Approved | 27742486 |
DrugRepV_2322 | Hydroxyurea | Antineoplastic and Immunomodulating Agents | Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.83370655 %) | Approved | 27742486 |
DrugRepV_2323 | Geniposide | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.7860683 %) | NA | 27742486 |
DrugRepV_2324 | Isoniazid | Antiinfectives For Systemic Use | Tuberculosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.74356574 %) | Approved, Investigational | 27742486 |
DrugRepV_2325 | Lapatinib | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.71161747 %) | Approved, Investigational | 27742486 |
DrugRepV_2326 | Dyclonine Hydrochloride | Nervous System | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.70472644 %) | Approved | 27742486 |
DrugRepV_2327 | Moxonidine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.70472644 %) | Approved, Investigational | 27742486 |
DrugRepV_2328 | Ketoconazole | Antiinfectives For Systemic Use | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.68563359 %) | Approved, Investigational | 27742486 |
DrugRepV_2329 | Chloroxine | NA | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.67704383 %) | Approved | 27742486 |
DrugRepV_2330 | Rosiglitazone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.65071465 %) | Approved | 27742486 |
DrugRepV_2331 | Milnacipran Hydrochloride | Nervous System | Depressive disorder | Fibromyalgia pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.63202363 %) | Approved, Investigational | 27742486 |
DrugRepV_2332 | Metformin Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.60501062 %) | Approved | 27742486 |
DrugRepV_2333 | Chenodiol | Alimentary Tract and Metabolism | Radiolucent Cholestrol gallstones | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.59183631 %) | Approved | 27742486 |
DrugRepV_2334 | Finasteride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.57558611 %) | Approved | 27742486 |
DrugRepV_2335 | Lornoxicam | Musculo-Skeletal System | Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.49164883 %) | Approved, Investigational | 27742486 |
DrugRepV_2336 | Omeprazole | Alimentary Tract and Metabolism | Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.4755509 %) | Approved | 27742486 |
DrugRepV_2337 | Adiphenine Hydrochloride | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.4400476 %) | NA | 27742486 |
DrugRepV_2338 | Posaconazole | Antiinfectives For Systemic Use | Fungal infections (Aspergillus and Candida infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.43393568 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2339 | Dienogest | Genito Urinary System and Sex Hormones | Endometriosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.3635241 %) | Approved | 27742486 |
DrugRepV_2340 | Formoterol Hemifumarate | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.36046959 %) | Approved, Investigational | 27742486 |
DrugRepV_2341 | Gadodiamide | Various | Intravenous use in MRI to visualize lesions | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.33933034 %) | Approved, Investigational | 27742486 |
DrugRepV_2342 | Fluocinolone Acetonide | Cardiovascular agents; Dermatologicals; Sensory Organ; Sensory Organ | Chronic non-infectious uveitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.307845 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2343 | Protionamide | Antiinfectives For Systemic Use | MDR-TB | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.29332873 %) | Approved, Investigational | 27742486 |
DrugRepV_2344 | Doxazosin Mesylate | Cardiovascular agents | Hypertension and Hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.283278 %) | Approved | 27742486 |
DrugRepV_2345 | Meptazinol Hydrochloride | Nervous System | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.28059603 %) | Experimental | 27742486 |
DrugRepV_2346 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.27014953 %) | Approved | 27742486 |
DrugRepV_2347 | Amoxicillin Sodium | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.26461637 %) | Approved | 27742486 |
DrugRepV_2348 | Ciclopirox | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.26315249 %) | Approved | 27742486 |
DrugRepV_2349 | Phenylephrine Hydrochloride | Cardiovascular agents; Respiratory System; Sensory Organ | Nasal congestion | Hypotension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.23716921 %) | Approved | 27742486 |
DrugRepV_2350 | Tranexamic Acid | Blood and Blood Forming Organs | Hemorrhage | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.23343185 %) | Approved | 27742486 |
DrugRepV_2351 | Loperamide Hydrochloride | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.23233156 %) | Approved | 27742486 |
DrugRepV_2352 | Pramiracetam | Antipsychotic | Alzheimer's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.22427984 %) | Approved | 27742486 |
DrugRepV_2353 | Etoposide | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.1881398 %) | Approved | 27742486 |
DrugRepV_2354 | Cephradine | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.17042436 %) | Approved | 27742486 |
DrugRepV_2355 | Methylthiouracil | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Hyperthyroidism | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.1440867 %) | Experimental | 27742486 |
DrugRepV_2356 | Metoprolol Tartrate | Cardiovascular agents | Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.12858015 %) | Approved, Investigational | 27742486 |
DrugRepV_2357 | Mecarbinate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.00956049 %) | NA | 27742486 |
DrugRepV_2358 | Sitafloxacin Hydrate | Antiinfectives For Systemic Use | Bacterial infections (respiratory and urinary tract infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.96036077 %) | Experimental, Investigational | 27742486 |
DrugRepV_2359 | Nefiracetam | Neurologic-agent | Alzheimer's Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.954445 %) | Investigational | 27742486 |
DrugRepV_2360 | Enoxacin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.93176568 %) | Approved | 27742486 |
DrugRepV_2361 | Quetiapine Fumarate | Nervous System | Schizophrenia | Bipolar disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.90178299 %) | Approved | 27742486 |
DrugRepV_2362 | Allopurinol Sodium | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.87428814 %) | Approved | 27742486 |
DrugRepV_2363 | Clofibrate | Cardiovascular agents | Hyperlipoproteinemia type III | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.86775626 %) | Approved | 27742486 |
DrugRepV_2364 | Olopatadine Hydrochloride | Sensory Organ | Allergic conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.86546695 %) | Approved | 27742486 |
DrugRepV_2365 | Benztropine Mesylate | Nervous System | Parkinson disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.84775979 %) | Approved | 27742486 |
DrugRepV_2366 | Dorzolamide Hydrochloride | Sensory Organ | Open-angle glaucoma and ocular hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.81420444 %) | Approved | 27742486 |
DrugRepV_2367 | Buflomedil Hydrochloride | Cardiovascular agents | Claudication and peripheral arterial disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.79867437 %) | NA | 27742486 |
DrugRepV_2368 | Ampicillin Sodium | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.75763916 %) | Approved | 27742486 |
DrugRepV_2369 | Duloxetine Hydrochloride | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.74588077 %) | Approved | 27742486 |
DrugRepV_2370 | Cytidine | NA | Biopolar Depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.69043453 %) | Experimental | 27742486 |
DrugRepV_2371 | Bromhexine Hydrochloride | Respiratory System | Respiratory disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.68488038 %) | Approved | 27742486 |
DrugRepV_2372 | Adapalene | Dermatologicals | Acne vulgaris | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.66633546 %) | Approved | 27742486 |
DrugRepV_2373 | Clorsulon | Veterinary medicine | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.66288958 %) | Vet approved | 27742486 |
DrugRepV_2374 | Enalaprilat Dihydrate | Cardiovascular Agents | Hypertension and symptomatic congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.61173617 %) | Approved | 27742486 |
DrugRepV_2375 | Bicalutamide | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.5677801 %) | Approved | 27742486 |
DrugRepV_2376 | Ozagrel Hydrochloride | Ophthalmic-agent | Dry eye syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.56463314 %) | Investigational | 27742486 |
DrugRepV_2377 | Azatadine Dimaleate | Respiratory System | Respiratory mucosal congestion and allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.55959216 %) | Approved | 27742486 |
DrugRepV_2378 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.53351293 %) | Approved | 27742486 |
DrugRepV_2379 | Fluticasone propionate | Respiratory System | Asthma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.49959478 %) | Approved | 27742486 |
DrugRepV_2380 | Alfuzosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.46993265 %) | Approved | 27742486 |
DrugRepV_2381 | Niacin | NA | Hyperlipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.44049164 %) | Approved, Investigational, Nutraceutical | 27742486 |
DrugRepV_2382 | Cleviprex | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.43173855 %) | Approved | 27742486 |
DrugRepV_2383 | Bacitracin Zinc | Antiinfectives For Systemic Use | Pneumonia and empyema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.42855269 %) | Approved | 27742486 |
DrugRepV_2384 | Potassium Iodide | Sensory Organ; Various | Hyperthyroidism | Thyrotoxicosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.4041496 %) | Approved | 27742486 |
DrugRepV_2385 | Meclizine Dihydrochloride | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.40144725 %) | Approved | 27742486 |
DrugRepV_2386 | Gliquidone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.39646573 %) | Approved | 27742486 |
DrugRepV_2387 | Risedronic Acid | Musculo-Skeletal System | Paget's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.38707257 %) | Approved | 27742486 |
DrugRepV_2388 | Albendazole oxide | NA | Parasitic infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.36721682 %) | Experimental | 27742486 |
DrugRepV_2389 | Temocapril Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Diabetic nephropathy | Improvement of prognosis for coronary artery diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.35963363 %) | Experimental, Investigational | 27742486 |
DrugRepV_2390 | Argatroban | Blood and Blood Forming Organs | Coagulation disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.35584553 %) | Approved | 27742486 |
DrugRepV_2391 | Clonidine Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.34543683 %) | Approved | 27742486 |
DrugRepV_2392 | Geniposidic Acid | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.33842957 %) | NA | 27742486 |
DrugRepV_2393 | Cyclophosphamide Monohydrate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.30836213 %) | Approved | 27742486 |
DrugRepV_2394 | Nebivolol | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.30490861 %) | Approved, Investigational | 27742486 |
DrugRepV_2395 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.2767148 %) | Investigational | 27742486 |
DrugRepV_2396 | Trichlormethiazide | Cardiovascular agents | Oedema and Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.27400898 %) | Approved | 27742486 |
DrugRepV_2397 | Lafutidine | Alimentary Tract and Metabolism | Peptic Ulcer | Pneumonia | Gastroesophageal Reflux Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.27113814 %) | Investigational | 27742486 |
DrugRepV_2398 | Trilostane | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Cushing's syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.24049946 %) | Approved | 27742486 |
DrugRepV_2399 | Paeoniflorin | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.22636429 %) | NA | 27742486 |
DrugRepV_2400 | Lansoprazole | Alimentary Tract and Metabolism | Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.21219908 %) | Approved, Investigational | 27742486 |
DrugRepV_2401 | Budesonide | Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System | Crohn disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.20587616 %) | Approved | 27742486 |
DrugRepV_2402 | Strontium Ranelate | Musculo-Skeletal System | Osteoporosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.19592095 %) | Approved, Withdrawn | 27742486 |
DrugRepV_2403 | Clindamycin Hydrochloride | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.19411786 %) | Approved | 27742486 |
DrugRepV_2404 | Spectinomycin Hydrochloride | Antiinfectives For Systemic Use | Bacterial infections (Gonorrheal urethritis and proctitis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.18634054 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2405 | Nicorandil | Cardiovascular agents | Acute coronary syndromes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.17516391 %) | Approved, Investigational | 27742486 |
DrugRepV_2406 | Mizolastine | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.16794907 %) | Investigational | 27742486 |
DrugRepV_2407 | Adenine | NA | Nutritional supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.12499687 %) | Approved | 27742486 |
DrugRepV_2408 | Decitabine | Antineoplastic and Immunomodulating Agents | Myelodysplastic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.12473547 %) | Approved | 27742486 |
DrugRepV_2409 | Epinephrine Bitartrate | Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory | Severe allergic reactions (including anaphylaxis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.09263056 %) | Approved | 27742486 |
DrugRepV_2410 | Clomipramine Hydrochloride | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.09263056 %) | Approved | 27742486 |
DrugRepV_2411 | Bexarotene | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.0549399 %) | Approved | 27742486 |
DrugRepV_2412 | Meloxicam | Musculo-Skeletal System | Arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.96940127 %) | Approved, Vet approved | 27742486 |
DrugRepV_2413 | Entacapone | Nervous System | Parkinson Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.96747673 %) | Approved | 27742486 |
DrugRepV_2414 | Flunarizine Dihydrochloride | Nervous System | Migraine | Vertigo | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.96747673 %) | Approved | 27742486 |
DrugRepV_2415 | Adenine Sulfate | NA | Nutritional supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.95953472 %) | Approved | 27742486 |
DrugRepV_2416 | Artemisinin | Antiparasitic products, Insectisides and Repellents | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.94527744 %) | Experimental | 27742486 |
DrugRepV_2417 | Mitotane | Antineoplastic and Immunomodulating Agents | Adrenocortical tumours | Cushing's syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.940259 %) | Approved | 27742486 |
DrugRepV_2418 | L-Adrenaline | Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory | Allergic reactions (including anaphylaxis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.93700765 %) | Approved, Vet approved | 27742486 |
DrugRepV_2419 | Ranolazine | Cardiovascular agents | Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.92187432 %) | Approved, Investigational | 27742486 |
DrugRepV_2420 | Altretamine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.89361145 %) | Approved | 27742486 |
DrugRepV_2421 | Manidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.86580948 %) | Approved, Investigational | 27742486 |
DrugRepV_2422 | Imiquimod | Dermatologicals | Genital and perianal warts/condyloma acuminata | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.85929889 %) | Approved, Investigational | 27742486 |
DrugRepV_2423 | Vardenafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.82388881 %) | Approved | 27742486 |
DrugRepV_2424 | Sulfameter | Antiinfectives For Systemic Use | Leprosy | Urinary | Respiratory tract infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.81863222 %) | Approved | 27742486 |
DrugRepV_2425 | Quinapril Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.78829028 %) | Approved, Investigational | 27742486 |
DrugRepV_2426 | Norfloxacin | Antiinfectives For Systemic Use | Urinary tract infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.69457675 %) | Approved | 27742486 |
DrugRepV_2427 | Chlorprothixene | Nervous System | Psychosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.68794785 %) | Approved | 27742486 |
DrugRepV_2428 | L-Glutamine | Alimentary Tract and Metabolism | Nutritional supplementation | Sickle cell disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.67790051 %) | Approved, Investigational, Nutraceutical | 27742486 |
DrugRepV_2429 | Fluvoxamine Maleate | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.66473263 %) | Approved, Investigational | 27742486 |
DrugRepV_2430 | Sulindac | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.66082495 %) | Approved, Investigational | 27742486 |
DrugRepV_2431 | Mitiglinide Calcium | Alimentary Tract and Metabolism | Type 2 diabetes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.63590267 %) | Investigational | 27742486 |
DrugRepV_2432 | Trazodone Hydrochloride | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.62662677 %) | Approved, Investigational | 27742486 |
DrugRepV_2433 | Rocuronium Bromide | Musculo-Skeletal System | Muscle fasciculation caused by succinylcholine | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.57246722 %) | Approved | 27742486 |
DrugRepV_2434 | Sarafloxacin Hydrochloride | Antibacterial | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.52020966 %) | Vet approved, Withdrawn | 27742486 |
DrugRepV_2435 | Sulfadoxine | Antiparasitic | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.46534855 %) | Approved, Investigational | 27742486 |
DrugRepV_2436 | Lomustine | Antineoplastic and Immunomodulating Agents | Brain tumor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.46226348 %) | Approved, Investigational | 27742486 |
DrugRepV_2437 | Silodosin | Genito Urinary System and Sex Hormones | Prostatic hyperplasia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.43672555 %) | Approved | 27742486 |
DrugRepV_2438 | Rimantadine | Antiinfectives For Systemic Use | Influenza A virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.43192971 %) | Approved, Investigational | 27742486 |
DrugRepV_2439 | Rifapentine | Antiinfectives For Systemic Use | Tuberculosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.3653391 %) | Approved, Investigational | 27742486 |
DrugRepV_2440 | Racecadotril | Antibacterial | Diarrhea | Acute Diarrhea | Acute Gastroenteritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.33496745 %) | Investigational | 27742486 |
DrugRepV_2441 | Zoledronic Acid | Musculo-Skeletal System | Hypercalcemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.32603653 %) | Approved | 27742486 |
DrugRepV_2442 | Granisetron Hydrochloride | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.32603653 %) | Approved, Investigational | 27742486 |
DrugRepV_2443 | Betamethasone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Edocrine disorders, rheumatic disorders, collagen diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.2771865 %) | Approved | 27742486 |
DrugRepV_2444 | Pamidronate Disodium | Musculo-Skeletal System | Hypercalcemia associated with malignancy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.23979587 %) | Approved | 27742486 |
DrugRepV_2445 | Gatifloxacin | Antiinfectives For Systemic Use | Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.22310404 %) | Approved, Investigational | 27742486 |
DrugRepV_2446 | Moexipril Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.15869259 %) | Approved | 27742486 |
DrugRepV_2447 | Raltegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.14736269 %) | Approved | 27742486 |
DrugRepV_2448 | Cefoperazone | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.13001149 %) | Approved | 27742486 |
DrugRepV_2449 | Tetracycline Hydrochloride | Antiinfectives For Systemic Use | Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.08422039 %) | Approved, Vet approved | 27742486 |
DrugRepV_2450 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.05561841 %) | Approved | 27742486 |
DrugRepV_2451 | Bifonazole | Dermatologicals | Fungal infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.03205443 %) | Approved | 27742486 |
DrugRepV_2452 | Bisoprolol | Cardiovascular agents | Cardiovascular disease, angina pectoris and myocardial infarction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.01316496 %) | Approved | 27742486 |
DrugRepV_2453 | Rosiglitazone Maleate | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (1.00342918 %) | Approved, Investigational | 27742486 |
DrugRepV_2454 | Ondansetron Hydrochloride | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.99825786 %) | Approved | 27742486 |
DrugRepV_2455 | Sulphadimethoxine | Antiinfectives For Systemic Use | Respiratory infection | Urinary tract infection | Enteric infection | Soft tissue infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.99278461 %) | Approved, Vet approved | 27742486 |
DrugRepV_2456 | Masitinib | Antineoplastic and Immunomodulating Agents | Mast cell tumors in dogs | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.95794841 %) | Investigational, Vet approved | 27742486 |
DrugRepV_2457 | Amikacin Hydrate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.87227544 %) | Approved | 27742486 |
DrugRepV_2458 | Acyclovir | Dermatologicals; Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Herpes simplex, Zoster and varicella zoster) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.8679278 %) | Approved | 27742486 |
DrugRepV_2459 | Pyrazinamide | Antiinfectives For Systemic Use | Tuberculosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.85917346 %) | Approved, Investigational | 27742486 |
DrugRepV_2460 | Triamcinolone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.85708189 %) | Approved | 27742486 |
DrugRepV_2461 | Tenoxicam | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Backache | Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.85680778 %) | Approved | 27742486 |
DrugRepV_2462 | Propafenone | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.83756587 %) | Approved | 27742486 |
DrugRepV_2463 | Dexamethasone Acetate | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.81918681 %) | Approved | 27742486 |
DrugRepV_2464 | Megestrol Acetate | Genito Urinary System and Sex Hormones | Anorexia | Cachexia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.80324191 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2465 | Sodium Butyrate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.80232337 %) | NA | 27742486 |
DrugRepV_2466 | Mometasone Furoate | Dermatologicals and Respiratory System | Asthma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.77748045 %) | Approved, Vet approved | 27742486 |
DrugRepV_2467 | Xylometazoline Hydrochloride | Respiratory System; Sensory Organ | Nasal congestion and minor inflammation due to allergies or colds | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.77290647 %) | Approved | 27742486 |
DrugRepV_2468 | Gestodene | Genito Urinary System and Sex Hormones | Progestogen hormonal contraceptive | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.76107127 %) | Investigational | 27742486 |
DrugRepV_2469 | Milrinone | Cardiovascular agents | Cardiotonic agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.70603205 %) | Approved | 27742486 |
DrugRepV_2470 | Cilnidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.67413581 %) | Approved | 27742486 |
DrugRepV_2471 | Azelnidipine | NA | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.64469838 %) | Approved | 27742486 |
DrugRepV_2472 | Anagrelide Hydrochloride | Antineoplastic and Immunomodulating Agents | Thrombocytosis and chronic myeloid leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.62449045 %) | Approved | 27742486 |
DrugRepV_2473 | Levonorgestrel | Genito Urinary System and Sex Hormones | Menopausal and postmenopausal disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.60239654 %) | Approved, Investigational | 27742486 |
DrugRepV_2474 | Sulfisoxazole | Antiinfectives For Systemic Use; Sensory Organ | Urinary tract infections | Meningococcal meningitis | Acute otitis media | Trachoma | Inclusion conjunctivitis | Nocardiosis | Chancroid | Toxoplasmosis | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.58656517 %) | Approved, Vet approved | 27742486 |
DrugRepV_2475 | Acadesine | Cardiovascular agents | Cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.50184624 %) | Approved | 27742486 |
DrugRepV_2476 | Ethionamide | Antiinfectives For Systemic Use | Tuberculosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.45109184 %) | Approved | 27742486 |
DrugRepV_2477 | Mestranol | NA | Contraception | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.44756785 %) | Approved | 27742486 |
DrugRepV_2478 | Streptomycin Sulfate | Antiinfectives For Systemic Use | Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.42772783 %) | Approved, Vet approved | 27742486 |
DrugRepV_2479 | Nizatidine | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.40022928 %) | Approved | 27742486 |
DrugRepV_2480 | Vidarabine | Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.36868435 %) | Approved | 27742486 |
DrugRepV_2481 | Dopamine Hydrochloride | Cardiovascular agents | Arrythmias and arterial hypotension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.35461971 %) | Approved | 27742486 |
DrugRepV_2482 | Butoconazole Nitrate | Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.33976627 %) | Approved | 27742486 |
DrugRepV_2483 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.33541797 %) | Approved | 27742486 |
DrugRepV_2484 | Dacarbazine | Antineoplastic and Immunomodulating Agents | Hodgkin disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.32719355 %) | Approved | 27742486 |
DrugRepV_2485 | Genistein | Antihelmintic | Prostate cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.32554274 %) | Investigational | 27742486 |
DrugRepV_2486 | Cefditoren Pivoxil | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.31336219 %) | Approved | 27742486 |
DrugRepV_2487 | Esomeprazole Sodium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.29986636 %) | Approved | 27742486 |
DrugRepV_2488 | Aspartame | NA | Diet supplement and sugar substitute | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.28008959 %) | Approved | 27742486 |
DrugRepV_2489 | Amfebutamone | Nervous System | Depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.27113824 %) | Approved | 27742486 |
DrugRepV_2490 | Risedronate Sodium | Musculo-Skeletal System | Paget's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.24157209 %) | Approved, Investigational | 27742486 |
DrugRepV_2491 | Guaifenesin | Respiratory System | Cold | Bronchitis or other breathing illnesses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.24064615 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2492 | Dexrazoxane Hydrochloride | Various | Cardiomyopathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.23802475 %) | Approved | 27742486 |
DrugRepV_2493 | Scopine | Alimentary Tract And Metabolism; Nervous System; Sensory Organ | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.22869183 %) | NA | 27742486 |
DrugRepV_2494 | Curcumin | NA | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.21930657 %) | Approved | 27742486 |
DrugRepV_2495 | Ramelteon | Nervous System | Insomnia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.19581857 %) | Approved, Investigational | 27742486 |
DrugRepV_2496 | Deflazacort | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Duchenne muscular dystrophy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.19023033 %) | Approved | 27742486 |
DrugRepV_2497 | Procarbazine Hydrochloride | Antineoplastic and Immunomodulating Agents | Hodgkin's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.16145424 %) | Approved | 27742486 |
DrugRepV_2498 | Cephalomannine | Antineoplastic | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.14550814 %) | NA | 27742486 |
DrugRepV_2499 | Donepezil Hydrochloride | Nervous System | Dementia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.11302961 %) | Approved | 27742486 |
DrugRepV_2500 | Olmesartan Medoxomil | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.09317819 %) | Approved, Investigational | 27742486 |
DrugRepV_2501 | Disodium Cromoglycate | Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System; Sensory Or | Allergy and asthma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.0865219 %) | Approved | 27742486 |
DrugRepV_2502 | Meglumine | Antiparasitic products, Insectisides and Repellents | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.08526202 %) | Approved | 27742486 |
DrugRepV_2503 | Isoprenaline Hydrochloride | Cardiovascular agents | Heart block | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.06631438 %) | Approved, Investigational | 27742486 |
DrugRepV_2504 | Tizanidine Hydrochloride | Musculo-Skeletal System | Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.04828156 %) | Approved, Investigational | 27742486 |
DrugRepV_2505 | Dofetilide | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.03153927 %) | Approved | 27742486 |
DrugRepV_2506 | Nelarabine | Antineoplastic and Immunomodulating Agents | T-cell acute lymphoblastic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.02495853 %) | Approved, Investigational | 27742486 |
DrugRepV_2507 | L-Arginine Hydrochloride | Blood and Blood Forming Organs | Nutritional supplementation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.02074722 %) | Investigational, Nutraceutical | 27742486 |
DrugRepV_2508 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (100 %) | Approved | 27742486 |
DrugRepV_2509 | Niflumic Acid | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Decrease (100 %) | Approved | 27742486 |
DrugRepV_2510 | Maraviroc | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0137712 %) | Approved, Investigational | 27742486 |
DrugRepV_2511 | Carbenicillin Disodium | Antiinfectives For Systemic Use | Urinary tract infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0151285 %) | Approved | 27742486 |
DrugRepV_2512 | Tetracaine Hydrochloride | Dermatologicals | Local dermal analgesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0174276 %) | Approved, Vet approved | 27742486 |
DrugRepV_2513 | Methscopolamine | Alimentary Tract And Metabolism; Sensory Organ | Peptic ulcers | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0240882 %) | Approved | 27742486 |
DrugRepV_2514 | Phenindione | Blood and Blood Forming Organs | Cardiomyopathy, atrial fibrillation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.0791815 %) | Approved, Investigational | 27742486 |
DrugRepV_2515 | Talc | NA | Rashes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.1085991 %) | Approved | 27742486 |
DrugRepV_2516 | Ketotifen Fumarate | Respiratory System | Atopic asthma | Conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.1370416 %) | Approved | 27742486 |
DrugRepV_2517 | Clarithromycin | Antiinfectives For Systemic Use | Microbial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.1486584 %) | Approved | 27742486 |
DrugRepV_2518 | Ganciclovir | Antiinfectives For Systemic Use | Cytomegalovirus infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.183847 %) | Approved, Investigational | 27742486 |
DrugRepV_2519 | Rosiglitazone Hydrochloride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.2146764 %) | Approved | 27742486 |
DrugRepV_2520 | Irbesartan | Cardiovascular agents | Hypertension | Diabetic nephropathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.2498496 %) | Approved, Investigational | 27742486 |
DrugRepV_2521 | Pregnenolone | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.2797662 %) | Approved, Experimental | 27742486 |
DrugRepV_2522 | Pyridostigmine bromide | Nervous System | Myasthenia gravis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.333684 %) | Approved, Investigational | 27742486 |
DrugRepV_2523 | Nadifloxacin | Dermatologicals | Acne Vulgaris | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.3986672 %) | Investigational | 27742486 |
DrugRepV_2524 | Gimeracil | Anticancer | Gastric cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4276036 %) | Approved | 27742486 |
DrugRepV_2525 | Altrenogest | Veterinary medicine | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4278845 %) | Approved, Vet Approved | 27742486 |
DrugRepV_2526 | Edaravone | Neurologic-agent | Amyotrophic lateral scleorosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4295646 %) | Approved | 27742486 |
DrugRepV_2527 | Acetylcholine Chloride | Sensory Organ | Ophthalmological Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4447588 %) | Approved | 27742486 |
DrugRepV_2528 | Artemether | Antiparasitic products, Insectisides and Repellents | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4769483 %) | Approved | 27742486 |
DrugRepV_2529 | Axitinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5090732 %) | Approved | 27742486 |
DrugRepV_2530 | Moxifloxacin Hydrochloride | Antiinfectives For Systemic Use | Sinusitis | Pneumonia | Chronic bronchitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5365847 %) | Approved, Investigational | 27742486 |
DrugRepV_2531 | Meropenem | Antiinfectives For Systemic Use | Bacterial infections (Skin infection) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5411877 %) | Approved, Investigational | 27742486 |
DrugRepV_2532 | Methocarbamol | Musculo-Skeletal System | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5777085 %) | Approved, Vet approved | 27742486 |
DrugRepV_2533 | Pimobendan | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.5850328 %) | Vet approved | 27742486 |
DrugRepV_2534 | Vandetanib | Antineoplastic and Immunomodulating Agents | Medullary thyroid cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.588259 %) | Approved | 27742486 |
DrugRepV_2535 | FK-506 | Dermatologicals; Antineoplastic and Immunomodulating Agents | Liver transplantation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6057741 %) | Approved | 27742486 |
DrugRepV_2536 | Paclitaxel | Antineoplastic and Immunomodulating Agents | Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6093096 %) | Approved | 27742486 |
DrugRepV_2537 | Naltrexone Hydrochloride | Nervous System | Alcohol dependence | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6142901 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2538 | Alibendol | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6238122 %) | NA | 27742486 |
DrugRepV_2539 | Vicriviroc Malate | NA | AIDS | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6325066 %) | Investigational | 27742486 |
DrugRepV_2540 | Valacyclovir Hydrochloride | Antiinfectives For Systemic Use | Herpes simplex and Zoster virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6677761 %) | Approved | 27742486 |
DrugRepV_2541 | Disulfiram | Nervous System | Chronic alcoholism | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6684287 %) | Approved | 27742486 |
DrugRepV_2542 | Sodium orthovanadate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.6967088 %) | NA | 27742486 |
DrugRepV_2543 | Cefaclor | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.7251215 %) | Approved | 27742486 |
DrugRepV_2544 | Tretinoin | Dermatologicals; Antineoplastic and Immunomodulating Agents | Acne | Photodamaged skin | Keratinization disorders such as ichthyosis and keratosis follicularis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.7746726 %) | Approved | 27742486 |
DrugRepV_2545 | Irsogladine | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8011514 %) | Investigational | 27742486 |
DrugRepV_2546 | Ciprofloxacin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8107955 %) | Approved | 27742486 |
DrugRepV_2547 | Orphenadrine Citrate | Musculo-Skeletal System | Parkinson disease and Muscle spasm | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8107955 %) | Approved | 27742486 |
DrugRepV_2548 | Sodium salicylate | Nervous System | Acne | Psoriasis | Callouses | Corns Keratosis pilaris | Warts | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8129041 %) | Approved | 27742486 |
DrugRepV_2549 | Diethylstilbestrol | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.85143 %) | Approved | 27742486 |
DrugRepV_2550 | Albendazole | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8595872 %) | Approved | 27742486 |
DrugRepV_2551 | Tobramycin | Antiinfectives For Systemic Use; Sensory Organ | Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8678849 %) | Approved, Investigational | 27742486 |
DrugRepV_2552 | Diltiazem Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.874358 %) | Approved | 27742486 |
DrugRepV_2553 | Loteprednol Etabonate | Sensory Organ | Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8962545 %) | Approved | 27742486 |
DrugRepV_2554 | Oxytetracycline dihydrate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.9136131 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2555 | Flubendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.9381124 %) | Experimental, Withdrawn | 27742486 |
DrugRepV_2556 | Oxybutynin Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.9623606 %) | Approved, Investigational | 27742486 |
DrugRepV_2557 | Aztreonam | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.9905633 %) | Approved | 27742486 |
DrugRepV_2558 | Ranitidine | Alimentary Tract and Metabolism | Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0007669 %) | Approved | 27742486 |
DrugRepV_2559 | Phentolamine Mesilate | Cardiovascular agents | Pheochromocytoma | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.022123 %) | Approved | 27742486 |
DrugRepV_2560 | Cilazapril Monohydrate | Cardiovascular agents | Hypertension and heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0262964 %) | Approved | 27742486 |
DrugRepV_2561 | Mirtazapine | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0396288 %) | Approved | 27742486 |
DrugRepV_2562 | Docosanol | Dermatologicals | Herpes simplex episodes | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.0813812 %) | Approved | 27742486 |
DrugRepV_2563 | Detomidine Hydrochloride | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.086047 %) | Approved, Vet Approved | 27742486 |
DrugRepV_2564 | Hydroxyflutamide | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.1400626 %) | NA | 27742486 |
DrugRepV_2565 | Ginkgolide A | Plant extract | Inflammatory disorder | immunological disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.1811648 %) | Nutraceutical | 27742486 |
DrugRepV_2566 | Lincomycin Hydrochloride | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.1874718 %) | Approved, Vet approved | 27742486 |
DrugRepV_2567 | Pralatrexate | Antineoplastic and Immunomodulating Agents | T-cell lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.1883229 %) | Approved, Investigational | 27742486 |
DrugRepV_2568 | Oxacillin Sodium Monohydrate | Antiinfectives For Systemic Use | Staphylococci infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2220202 %) | Approved, Investigational | 27742486 |
DrugRepV_2569 | Entecavir Hydrate | Antiinfectives For Systemic Use | Hepatitis B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2373625 %) | Approved | 27742486 |
DrugRepV_2570 | Ursodiol | NA | Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.242893 %) | Approved | 27742486 |
DrugRepV_2571 | Bendamustine Hydrochloride | Antineoplastic and Immunomodulating Agents | Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2429281 %) | Approved | 27742486 |
DrugRepV_2572 | Camptothecin | Anticancer | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2458719 %) | Approved | 27742486 |
DrugRepV_2573 | Nimodipine | Cardiovascular agents | Subarachnoid hemorrhage (SAH) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2547481 %) | Approved, Investigational | 27742486 |
DrugRepV_2574 | BIBR-1048 | Blood and Blood Forming Organs | Thrombosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2578913 %) | Approved | 27742486 |
DrugRepV_2575 | Amprenavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2615469 %) | Approved | 27742486 |
DrugRepV_2576 | Isradipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2706832 %) | Approved, Investigational | 27742486 |
DrugRepV_2577 | Cimetidine | Alimentary Tract and Metabolism | Peptic ulcers, heartburn and acid indigestion | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3280471 %) | Approved | 27742486 |
DrugRepV_2578 | Rosuvastatin Calcium | Cardiovascular agents | Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3486114 %) | Approved | 27742486 |
DrugRepV_2579 | Chlormezanone | Musculo-Skeletal System | Anxiety and muscle spasm | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3558347 %) | Approved | 27742486 |
DrugRepV_2580 | Quinine Hydrochloride dihydrate | Antiparasitic products, Insectisides and Repellents | Malaria | Leg cramps | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3590955 %) | Approved | 27742486 |
DrugRepV_2581 | Salbutamol Sulfate | Respiratory System | Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3636934 %) | Approved, Vet approved | 27742486 |
DrugRepV_2582 | Vecuronium bromide | Musculo-Skeletal System | Non-depolarizing neuromuscular blocking agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3726313 %) | Approved | 27742486 |
DrugRepV_2583 | Darifenacin Hydrobromide | Genito Urinary System and Sex Hormones | Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3801387 %) | Approved | 27742486 |
DrugRepV_2584 | Flumequine | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3882128 %) | Withdrawn | 27742486 |
DrugRepV_2585 | Dexamethasone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3910252 %) | Approved | 27742486 |
DrugRepV_2586 | Bleomycin Sulfate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3921953 %) | Approved | 27742486 |
DrugRepV_2587 | Prednisolone Acetate | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3985941 %) | Approved, Vet approved | 27742486 |
DrugRepV_2588 | Oxybutynin | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4048985 %) | Approved, Investigational | 27742486 |
DrugRepV_2589 | Irinotecan | Antineoplastic and Immunomodulating Agents | Colorectal cancer | Small cell lung cancer | Cervical cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4109846 %) | Approved, Investigational | 27742486 |
DrugRepV_2590 | Sulfasalazine | Alimentary Tract and Metabolism | Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4225909 %) | Approved | 27742486 |
DrugRepV_2591 | Thalidomide | Antineoplastic and Immunomodulating Agents | Erythema nodosum leprosum | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.433969 %) | Approved, Investigational, Withdrawn | 27742486 |
DrugRepV_2592 | Bumetanide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4483238 %) | Approved | 27742486 |
DrugRepV_2593 | Articaine Hydrochloride | Nervous System | Anaesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.4948978 %) | Approved | 27742486 |
DrugRepV_2594 | Vitamin B12 | Blood and Blood Forming Organs | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5062413 %) | Approved | 27742486 |
DrugRepV_2595 | Erdosteine | Respiratory System | Chronic bronchitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5223486 %) | Approved | 27742486 |
DrugRepV_2596 | Methacycline Hydrochloride | NA | Acute bacterial exacerbations of chronic bronchitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5238499 %) | Approved, Investigational | 27742486 |
DrugRepV_2597 | Letrozole | Antineoplastic and Immunomodulating Agents | Breast cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5283999 %) | Approved, Investigational | 27742486 |
DrugRepV_2598 | Telbivudine | Antiinfectives For Systemic Use | Hepatitis B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5369604 %) | Approved | 27742486 |
DrugRepV_2599 | Methyldopa | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5755527 %) | Approved | 27742486 |
DrugRepV_2600 | Betaxolol Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5822028 %) | Approved | 27742486 |
DrugRepV_2601 | Phenacetin | Nervous System | Analgesic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5882537 %) | Withdrawn | 27742486 |
DrugRepV_2602 | Topotecan Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5991588 %) | Approved, Investigational | 27742486 |
DrugRepV_2603 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6028527 %) | Approved, Withdrawn | 27742486 |
DrugRepV_2604 | Riboflavin | Alimentary Tract and Metabolism | Vitamin B2 deficiency | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6151556 %) | Approved, Investigational, Nutraceutical, Vet approved | 27742486 |
DrugRepV_2605 | Dapoxetine Hydrochloride | Genito Urinary System and Sex Hormones | Premature ejaculation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6280168 %) | Approved | 27742486 |
DrugRepV_2606 | Lomefloxacin Hydrochloride | Antiinfectives For Systemic Use | Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6544832 %) | Approved, Investigational | 27742486 |
DrugRepV_2607 | Linezolid | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6567659 %) | Approved, Investigational | 27742486 |
DrugRepV_2608 | Exemestane | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6612547 %) | Approved | 27742486 |
DrugRepV_2609 | Nevirapine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.6918978 %) | Approved | 27742486 |
DrugRepV_2610 | 2-Methoxyestradiol | NA | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7014075 %) | Investigational | 27742486 |
DrugRepV_2611 | Felbamate | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7147317 %) | Approved | 27742486 |
DrugRepV_2612 | Felodipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7151698 %) | Approved, Investigational | 27742486 |
DrugRepV_2613 | Azathioprine | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis. | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.720627 %) | Approved | 27742486 |
DrugRepV_2614 | Fludarabine | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7238787 %) | Approved | 27742486 |
DrugRepV_2615 | Zonisamide | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7356315 %) | Approved | 27742486 |
DrugRepV_2616 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7449704 %) | Approved | 27742486 |
DrugRepV_2617 | Cisplatin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7493506 %) | Approved | 27742486 |
DrugRepV_2618 | Benazepril Hydrochloride | Cardiovascular agents | Hypertension, congestive heart failure and chronic renal failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7768175 %) | Approved | 27742486 |
DrugRepV_2619 | Nafamostat Mesylate | NA | Blood vessel coagulation | Hemorrhagic lesions | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7795584 %) | Investigational | 27742486 |
DrugRepV_2620 | Trospium Chloride | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7986713 %) | Approved | 27742486 |
DrugRepV_2621 | Propylthiouracil | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Hyperthyroidism | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8029587 %) | Approved, Investigational | 27742486 |
DrugRepV_2622 | Cilostazol | Blood and Blood Forming Organs | Intermittent claudication | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8044261 %) | Approved | 27742486 |
DrugRepV_2623 | Liranaftate | NA | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8068752 %) | NA | 27742486 |
DrugRepV_2624 | Scopine Hydrochloride | Alimentary Tract And Metabolism; Nervous System; Sensory Organ | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8166672 %) | Approved, Investigational | 27742486 |
DrugRepV_2625 | NAD | NA | Parkinson's disease | Chronic fatigue syndrome | Alzheimer's disease | Cardiovascular disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8213385 %) | Approved | 27742486 |
DrugRepV_2626 | Voriconazole | Antiinfectives For Systemic Use | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8244532 %) | Approved | 27742486 |
DrugRepV_2627 | Nitrendipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8300478 %) | Approved, Investigational | 27742486 |
DrugRepV_2628 | Leucovorin calcium | Various | Osteosarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8474034 %) | Approved | 27742486 |
DrugRepV_2629 | Vancomycin Hydrochloride | Alimentary Tract And Metabolism; Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8521766 %) | Approved | 27742486 |
DrugRepV_2630 | Pantothenic Acid | Alimentary Tract And Metabolism; Dermatologicals | Testicular torsion | Diabetic ulceration | Wound healing | Acne | Obesity | Diabetic peripheral polyneuropathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8616502 %) | Approved, Nutraceutical, Vet approved | 27742486 |
DrugRepV_2631 | Amitriptyline Hydrochloride | Nervous System | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.8631848 %) | Approved | 27742486 |
DrugRepV_2632 | Balofloxacin | Antibacterial | Bacterial infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9028632 %) | Approved | 27742486 |
DrugRepV_2633 | Zileuton | NA | Asthma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9379253 %) | Approved, Withdrawn | 27742486 |
DrugRepV_2634 | Clopidogrel | Blood and Blood Forming Organs | Myocardial infarction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.943957 %) | Approved | 27742486 |
DrugRepV_2635 | Rebamipide | Alimentary Tract and Metabolism | Stomach Ulcer | Keratoconjunctivitis Sicca | Gastric Adenoma | Early Gastric Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9454128 %) | Investigational | 27742486 |
DrugRepV_2636 | Amiloride Hydrochloride Dihydrate | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9573532 %) | Approved | 27742486 |
DrugRepV_2637 | Valproate Sodium | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.9922594 %) | Approved | 27742486 |
DrugRepV_2638 | Imatinib | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0019627 %) | Approved | 27742486 |
DrugRepV_2639 | Gallamine triethiodide | Musculo-Skeletal System | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0196399 %) | Approved | 27742486 |
DrugRepV_2640 | Levofloxacin | Antiinfectives For Systemic Use | Bacterial infections (Conjunctivitis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.028788 %) | Approved, Investigational | 27742486 |
DrugRepV_2641 | Phenoxybenzamine Hydrochloride | Cardiovascular agents | Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0355134 %) | Approved | 27742486 |
DrugRepV_2642 | Cephalexin | Antibiotics | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0410882 %) | Approved | 27742486 |
DrugRepV_2643 | Sumatriptan Succinate | Nervous System | Migraine disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0465676 %) | Approved, Investigational | 27742486 |
DrugRepV_2644 | Rapamycin | Antineoplastic and Immunomodulating Agents; Sensory Organ | Prophylaxis of organ rejection in patients receiving renal transplants | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.0495258 %) | Approved, Investigational | 27742486 |
DrugRepV_2645 | Cidofovir | Antiinfectives For Systemic Use | Cytomegalovirus infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1015434 %) | Approved | 27742486 |
DrugRepV_2646 | Pazopanib Hydrochloride | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1099434 %) | Approved | 27742486 |
DrugRepV_2647 | Esomeprazole Magnesium | Alimentary Tract and Metabolism | Acid-reflux disorders (GERD) and peptic ulcer disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1210661 %) | Approved | 27742486 |
DrugRepV_2648 | Pioglitazone | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1624894 %) | Approved, Investigational | 27742486 |
DrugRepV_2649 | Aminophylline | Respiratory System | Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1683375 %) | Approved | 27742486 |
DrugRepV_2650 | Bepotastine besilate | NA | Allergic rhinitis and uriticaria/puritus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1704391 %) | Approved | 27742486 |
DrugRepV_2651 | Clafen | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1776836 %) | Approved | 27742486 |
DrugRepV_2652 | Nepafenac | Sensory Organ | Inflammation associated with cataract surgery | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1896457 %) | Approved | 27742486 |
DrugRepV_2653 | Fluconazole | Antiinfectives For Systemic Use | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2384772 %) | Approved, Investigational | 27742486 |
DrugRepV_2654 | Trimethoprim | Antiinfectives For Systemic Use | Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2572502 %) | Approved | 27742486 |
DrugRepV_2655 | Dyphylline | Respiratory System | Chronic bronchitis and emphysema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2577836 %) | Approved | 27742486 |
DrugRepV_2656 | Fludarabine phosphate | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2595351 %) | Approved | 27742486 |
DrugRepV_2657 | Bimatoprost | Sensory Organ | Ocular Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2748636 %) | Approved | 27742486 |
DrugRepV_2658 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3323109 %) | Approved | 27742486 |
DrugRepV_2659 | Carboplatin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3400754 %) | Approved | 27742486 |
DrugRepV_2660 | Acarbose | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3477084 %) | Approved | 27742486 |
DrugRepV_2661 | Biotin | Alimentary Tract and Metabolism | Nutritional supplementation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3585021 %) | Approved | 27742486 |
DrugRepV_2662 | Fluocinonide | Dermatologicals | Eczema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3646739 %) | Approved, Investigational | 27742486 |
DrugRepV_2663 | Manidipine Dihydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3680473 %) | Approved, Investigational | 27742486 |
DrugRepV_2664 | Miglitol | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.380669 %) | Approved | 27742486 |
DrugRepV_2665 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3865744 %) | Approved | 27742486 |
DrugRepV_2666 | Candesartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.3946995 %) | Approved | 27742486 |
DrugRepV_2667 | Azlocillin Sodium salt | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4022354 %) | Approved | 27742486 |
DrugRepV_2668 | Moguisteine | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4037393 %) | NA | 27742486 |
DrugRepV_2669 | Cetirizine Dihydrochloride | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4358768 %) | Approved | 27742486 |
DrugRepV_2670 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4398466 %) | Approved | 27742486 |
DrugRepV_2671 | Tripelennamine Hydrochloride | Dermatologicals and Respiratory System | Gastrointestinal irritation | Asthma | HAY fever | Urticaria |Rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4469427 %) | Approved | 27742486 |
DrugRepV_2672 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.47799 %) | Approved, Investigational | 27742486 |
DrugRepV_2673 | Cefprozil Hydrate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4845708 %) | Approved | 27742486 |
DrugRepV_2674 | Hydralazine Hydrochloride | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4875991 %) | Approved | 27742486 |
DrugRepV_2675 | Gemfibrozil | Cardiovascular agents | Hyperlipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5184325 %) | Approved | 27742486 |
DrugRepV_2676 | Naftifine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5283589 %) | Approved | 27742486 |
DrugRepV_2677 | Aliskiren Hemifumarate | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5377825 %) | Approved | 27742486 |
DrugRepV_2678 | Amiloride Hydrochloride | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5420556 %) | Approved | 27742486 |
DrugRepV_2679 | Temsirolimus | Antineoplastic and Immunomodulating Agents | Renal cell carcinoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.55968 %) | Approved | 27742486 |
DrugRepV_2680 | Carbidopa | Neurologic-agent | Parkinson Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5784382 %) | Approved | 27742486 |
DrugRepV_2681 | Ramipril | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5841949 %) | Approved | 27742486 |
DrugRepV_2682 | Levetiracetam | Nervous System | Epilepsy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5916963 %) | Approved, Investigational | 27742486 |
DrugRepV_2683 | 10-DAB | NA | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.5981982 %) | NA | 27742486 |
DrugRepV_2684 | Cladribine | Antineoplastic and Immunomodulating Agents | Lymphoproliferative diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.6030286 %) | Approved | 27742486 |
DrugRepV_2685 | Oseltamivir phosphate | Antiinfectives For Systemic Use | Influenza A/B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.6044621 %) | Approved | 27742486 |
DrugRepV_2686 | Estriol | Genito Urinary System and Sex Hormones | Estrogen receptor | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.6485182 %) | Approved | 27742486 |
DrugRepV_2687 | Fesoterodine Fumarate | Genito Urinary System and Sex Hormones | Overactive bladder syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.7220164 %) | Approved | 27742486 |
DrugRepV_2688 | Chlorpromazine | Nervous System | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.7555603 %) | Approved | 27742486 |
DrugRepV_2689 | Daptomycin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.764086 %) | Approved | 27742486 |
DrugRepV_2690 | Capecitabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.7889064 %) | Approved | 27742486 |
DrugRepV_2691 | Ipratropium bromide | Respiratory System | Asthma | Chronic bronchitis | Emphysema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8135236 %) | Approved, Experimental | 27742486 |
DrugRepV_2692 | Dextrose | NA | Hypoglycemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8688015 %) | Approved | 27742486 |
DrugRepV_2693 | Cloxacillin Sodium | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8753795 %) | Approved | 27742486 |
DrugRepV_2694 | Chlorpheniramine Maleate | Respiratory System | Rhinitis, urticaria, allergy, common cold, asthma and hay fever | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8794966 %) | Approved | 27742486 |
DrugRepV_2695 | Atropine | Sensory Organ | Cholinesterase | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9146303 %) | Approved | 27742486 |
DrugRepV_2696 | Nilotinib | Antineoplastic and Immunomodulating Agents | Leukemias | Chronic myeloid leukemia (CML) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9152275 %) | Approved, Investigational | 27742486 |
DrugRepV_2697 | Fleroxacin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9243945 %) | Experimental | 27742486 |
DrugRepV_2698 | Tolterodine Tartrate | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9333711 %) | Approved, Investigational | 27742486 |
DrugRepV_2699 | Genipin | Plant extract | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9384281 %) | NA | 27742486 |
DrugRepV_2700 | Tenofovir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9691678 %) | Approved, Investigational | 27742486 |
DrugRepV_2701 | Pranoprofen | Sensory Organ | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9707089 %) | Experimental, Investigational | 27742486 |
DrugRepV_2702 | Metronidazole | Antiparasitic products, Insectisides and Repellents | Amebiasis | Vaginitis | Trichomonas infections | Giardiasis | Anaerobic bacteria | Treponemal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9895213 %) | Approved | 27742486 |
DrugRepV_2703 | Dichlorphenamide | Sensory Organ | Glaucoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.006092 %) | Approved | 27742486 |
DrugRepV_2704 | Sulbactam Sodium | Antiinfectives For Systemic Use | Bacterial infections (Skin infection) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0092385 %) | Approved | 27742486 |
DrugRepV_2705 | Tioxolone | Dermatologicals | Seborrhea or Seborrheic dermatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0190059 %) | Experimental | 27742486 |
DrugRepV_2706 | Sulfadiazine | Antiinfectives For Systemic Use | Rheumatic fever | Meningococcal meningitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0259808 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2707 | Vinblastine | Antineoplastic and Immunomodulating Agents | Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0262855 %) | Approved | 27742486 |
DrugRepV_2708 | Lisinopril | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0316803 %) | Approved, Investigational | 27742486 |
DrugRepV_2709 | Arecoline | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0469253 %) | Experimental | 27742486 |
DrugRepV_2710 | D-Cycloserine | Antiinfectives For Systemic Use | Antibiotic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.0661555 %) | Approved | 27742486 |
DrugRepV_2711 | Enalapril Maleate | Cardiovascular agents | Hypertension and Diabetic nephropathies | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1210281 %) | Approved | 27742486 |
DrugRepV_2712 | (R)-Baclofen | Musculo-Skeletal System | Spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1299275 %) | Approved | 27742486 |
DrugRepV_2713 | Perindopril erbumine | Cardiovascular agents | Hypertension | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.1490604 %) | Approved | 27742486 |
DrugRepV_2714 | Nicotinamide | Alimentary Tract and Metabolism | Dietary supplement | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2083988 %) | Approved, Investigational | 27742486 |
DrugRepV_2715 | Indacaterol Maleate | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2126007 %) | Approved | 27742486 |
DrugRepV_2716 | Abiraterone Acetate | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.222047 %) | Approved | 27742486 |
DrugRepV_2717 | Prasugrel | Blood and Blood Forming Organs | Acute coronary syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2301485 %) | Approved | 27742486 |
DrugRepV_2718 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2495137 %) | Approved, Investigational | 27742486 |
DrugRepV_2719 | Lacidipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2613206 %) | Approved, Investigational | 27742486 |
DrugRepV_2720 | Tenofovir disoproxil Fumarate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.295385 %) | Approved, Investigational | 27742486 |
DrugRepV_2721 | Adefovir dipivoxil | Antiinfectives For Systemic Use | Hepatitis B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.3056399 %) | Approved | 27742486 |
DrugRepV_2722 | Besifloxacin Hydrochloride | Sensory Organ | Bacterial conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.332664 %) | Approved | 27742486 |
DrugRepV_2723 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.356697 %) | Approved | 27742486 |
DrugRepV_2724 | Octopamine Hydrochloride | Cardiovascular agents | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.3569036 %) | NA | 27742486 |
DrugRepV_2725 | Sildenafil Citrate | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4050275 %) | Approved, Investigational | 27742486 |
DrugRepV_2726 | Saxagliptin | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.414562 %) | Approved | 27742486 |
DrugRepV_2727 | Ofloxacin | Antiinfectives For Systemic Use | Respiratory tract infections | Kidney infection | Skin infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4146475 %) | Approved | 27742486 |
DrugRepV_2728 | Pravastatin Sodium | Cardiovascular agents | Hypercholesterolemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4229682 %) | Approved | 27742486 |
DrugRepV_2729 | Creatinine | Neurologic-agent | Amyotrophic Lateral Sclerosis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4231528 %) | Investigational | 27742486 |
DrugRepV_2730 | Amlodipine Besylate | Cardiovascular agents | Hypertension and chronic stable angina | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4244387 %) | Approved | 27742486 |
DrugRepV_2731 | Rifabutin | Antiinfectives For Systemic Use | Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4674544 %) | Approved, Investigational | 27742486 |
DrugRepV_2732 | Adrucil | Antineoplastic and Immunomodulating Agents | Multiple actinic or solar keratoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4729205 %) | Approved | 27742486 |
DrugRepV_2733 | Phenytoin Sodium | Nervous System | Seizures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.4867115 %) | Approved, Vet approved | 27742486 |
DrugRepV_2734 | Sulbactam | Antiinfectives For Systemic Use | Bacterial infections (Skin infection) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5031618 %) | Approved | 27742486 |
DrugRepV_2735 | Ivabradine Hydrochloride | Cardiovascular agents | Angina pectoralis | Chronic heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5395934 %) | Approved | 27742486 |
DrugRepV_2736 | Benserazide | Neurologic-agent | Parkinson's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5576471 %) | Approved | 27742486 |
DrugRepV_2737 | Didanosine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5849038 %) | Approved | 27742486 |
DrugRepV_2738 | Fenbendazole | Antiparasitic products, Insectisides and Repellents | Helminthiasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.5894807 %) | Vet approved | 27742486 |
DrugRepV_2739 | Hygromycin B | Antibacterial | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.6080755 %) | Vet approved | 27742486 |
DrugRepV_2740 | Gabapentin Hydrochloride | Nervous System | Epilepsy (seizure) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.614607 %) | Approved | 27742486 |
DrugRepV_2741 | Natamycin | Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective | Fungal blepharitis | Conjunctivitis | Keratitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.6362172 %) | Approved | 27742486 |
DrugRepV_2742 | Carbamazepine | Nervous System | Epilepsy and pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.6723227 %) | Approved | 27742486 |
DrugRepV_2743 | Oxytetracycline | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.6733944 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2744 | Amantadine Hydrochloride | Nervous System | Influenza and Parkinson Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.6791464 %) | Approved | 27742486 |
DrugRepV_2745 | Aripiprazole | Nervous System | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.7508746 %) | Approved | 27742486 |
DrugRepV_2746 | Gabexate Mesylate | NA | Cancer | Ischemia-reperfusion injury | Pancreatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.7539063 %) | Investigational | 27742486 |
DrugRepV_2747 | Rivastigmine Tartrate | Nervous System | Dementia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.7832229 %) | Approved, Investigational | 27742486 |
DrugRepV_2748 | Dronedarone Hydrochloride | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.8605968 %) | Approved | 27742486 |
DrugRepV_2749 | Gabapentin | Nervous System | Epilepsy (seizure) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.8662068 %) | Approved | 27742486 |
DrugRepV_2750 | Bupivacaine Hydrochloride | Nervous System | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.8793995 %) | Approved | 27742486 |
DrugRepV_2751 | Marbofloxacin | NA | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.8874309 %) | Vet approved | 27742486 |
DrugRepV_2752 | Rolipram | Antidepressant | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.9578731 %) | Experimental | 27742486 |
DrugRepV_2753 | Telmisartan | Cardiovascular agents | Hypertension | Type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.9984663 %) | Approved, Investigational | 27742486 |
DrugRepV_2754 | Mesalamine | Alimentary Tract and Metabolism | Ulcerative colitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.0005942 %) | Approved | 27742486 |
DrugRepV_2755 | Cortisone Acetate | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Allergies, skin problems, asthma and arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.0138374 %) | Approved | 27742486 |
DrugRepV_2756 | Triamcinolone Acetonide | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.0201161 %) | Approved, Vet approved | 27742486 |
DrugRepV_2757 | Risperidone | Nervous System | Schizophrenia | Mood disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.0706996 %) | Approved, Investigational | 27742486 |
DrugRepV_2758 | Mercaptopurine | Antineoplastic and Immunomodulating Agents | Acute lymphatic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.11069 %) | Approved | 27742486 |
DrugRepV_2759 | Tiotropium Bromide Hydrate | Respiratory System | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1287058 %) | Approved | 27742486 |
DrugRepV_2760 | Streptozotocin | Antineoplastic and Immunomodulating Agents | Malignant neoplasms of pancreas (metastatic islet cell carcinoma) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1556333 %) | Approved, Investigational | 27742486 |
DrugRepV_2761 | Glimepiride | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1556333 %) | Approved | 27742486 |
DrugRepV_2762 | Diclofenac | Dermatologicals; Musculo-Skeletal System and Sensory Organ | Fever and pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1617635 %) | Approved | 27742486 |
DrugRepV_2763 | Taurine | NA | Nutritional supplementation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1985759 %) | Approved | 27742486 |
DrugRepV_2764 | Zalcitabine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome/AIDS | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.2270809 %) | Approved | 27742486 |
DrugRepV_2765 | Tebipenem pivoxil | Antibacterial | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.2767522 %) | NA | 27742486 |
DrugRepV_2766 | Rufinamide | Nervous System | Seizure disorder :- Lennox-Gastuat syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.2854179 %) | Approved | 27742486 |
DrugRepV_2767 | Oxaliplatin | Antineoplastic and Immunomodulating Agents | Colon Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.2965612 %) | Approved, Investigational | 27742486 |
DrugRepV_2768 | Alfacalcidol | Alimentary Tract and Metabolism | Hyperparathyroidism, Hypocalcemia and Osteodystropy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.3172474 %) | Approved | 27742486 |
DrugRepV_2769 | Triflusal | Blood and Blood Forming Organs | Thromboembolic disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.3917465 %) | Approved, Investigational | 27742486 |
DrugRepV_2770 | Ulipristal | Genito Urinary System and Sex Hormones | Emergency contraceptive and uterine fibroids | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4064062 %) | Approved | 27742486 |
DrugRepV_2771 | Methazolastone | Antineoplastic and Immunomodulating Agents | Refractory anaplastic astrocytoma | Glioblastoma multiforme | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4157601 %) | Approved, Investigational | 27742486 |
DrugRepV_2772 | Progesterone | Genito Urinary System and Sex Hormones | Infertility | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4329417 %) | Approved, Vet approved | 27742486 |
DrugRepV_2773 | Agomelatine | Nervous System | Depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.435983 %) | Approved | 27742486 |
DrugRepV_2774 | Droxidopa | Cardiovascular agents | Parkinson's Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4482179 %) | Approved | 27742486 |
DrugRepV_2775 | Flucytosine | Antiinfectives For Systemic Use | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4557163 %) | Approved, Investigational | 27742486 |
DrugRepV_2776 | Ethinyl estradiol | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4808177 %) | Approved | 27742486 |
DrugRepV_2777 | Sulfamerazine | Antiinfectives For Systemic Use | Bacterial infections (Bronchitis, prostatitis and urinary tract infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.4815833 %) | Approved, Vet approved | 27742486 |
DrugRepV_2778 | Ketorolac | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5175573 %) | Approved | 27742486 |
DrugRepV_2779 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5278588 %) | Approved, Investigational | 27742486 |
DrugRepV_2780 | BIBR 953 | NA | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5344416 %) | Approved | 27742486 |
DrugRepV_2781 | Betahistine Dihydrochloride | Nervous System | Vertigo assosicated with Méničre's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5509946 %) | Approved | 27742486 |
DrugRepV_2782 | Catharanthine | Plant Component | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.560762 %) | NA | 27742486 |
DrugRepV_2783 | Elvitegravir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5754617 %) | Approved | 27742486 |
DrugRepV_2784 | Naftopidil | Urologic-agent | Urinary Stent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.5810603 %) | Investigational | 27742486 |
DrugRepV_2785 | Bethanechol chloride | Nervous System | Neurogenic bladder dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6656964 %) | Approved | 27742486 |
DrugRepV_2786 | Indapamide | Cardiovascular agents | Hypertension | Edema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6882509 %) | Approved | 27742486 |
DrugRepV_2787 | DL-Adrenaline | Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory | Allergic reactions | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6935822 %) | Approved | 27742486 |
DrugRepV_2788 | Tolbutamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.6951294 %) | Approved, Investigational | 27742486 |
DrugRepV_2789 | Linagliptin | Alimentary Tract and Metabolism | Type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7159637 %) | Approved | 27742486 |
DrugRepV_2790 | Flurbiprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7319021 %) | Approved, Investigational | 27742486 |
DrugRepV_2791 | Abacavir Sulfate | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7456882 %) | Approved | 27742486 |
DrugRepV_2792 | Amlodipine | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7826838 %) | Approved | 27742486 |
DrugRepV_2793 | Tazarotene | Dermatologicals | Psoriasis, acne and sun damaged skin | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.7953339 %) | Approved | 27742486 |
DrugRepV_2794 | Torsemide | Cardiovascular agents | Edema and hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.8209892 %) | Approved | 27742486 |
DrugRepV_2795 | Roxithromycin | Antiinfectives For Systemic Use | Respiratory tract | Urinary and soft tissue infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.8220241 %) | Approved | 27742486 |
DrugRepV_2796 | Ibuprofen lysine | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.8737995 %) | Approved | 27742486 |
DrugRepV_2797 | Ondansetron | Alimentary Tract and Metabolism | Nausea | Vomiting | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.9010506 %) | Approved | 27742486 |
DrugRepV_2798 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.9388504 %) | Approved | 27742486 |
DrugRepV_2799 | Prilocaine | Nervous System | Anesthesia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.9717216 %) | Approved | 27742486 |
DrugRepV_2800 | Octocrylene | Dermatologicals | Sunburn | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.009058 %) | Approved | 27742486 |
DrugRepV_2801 | Lamivudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Hepatitis B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.0142414 %) | Approved | 27742486 |
DrugRepV_2802 | Idarubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Acute myeloid leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.0284839 %) | Approved | 27742486 |
DrugRepV_2803 | Maprotiline Hydrochloride | Nervous System | Bipolar depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.0613707 %) | Approved, Investigational | 27742486 |
DrugRepV_2804 | Rasagiline Mesylate | Nervous System | Idiopathic Parkinson's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.0889023 %) | Approved | 27742486 |
DrugRepV_2805 | Plerixafor octahydrochloride | Antineoplastic and Immunomodulating Agents | Mobilization of hematopoietic stem cells | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.1063153 %) | Approved | 27742486 |
DrugRepV_2806 | Docetaxel | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.1241227 %) | Approved | 27742486 |
DrugRepV_2807 | Varenicline tartrate | Nervous System | Nicotine dependence | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.1953001 %) | Approved | 27742486 |
DrugRepV_2808 | Metolazone | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.2375608 %) | Approved | 27742486 |
DrugRepV_2809 | Domperidone | Alimentary Tract and Metabolism | Dyspepsia, heartburn, epigastric pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.2614756 %) | Approved | 27742486 |
DrugRepV_2810 | Amorolfine Hydrochloride | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3091551 %) | Approved | 27742486 |
DrugRepV_2811 | Cefoselis Sulfate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3205301 %) | NA | 27742486 |
DrugRepV_2812 | Piroxicam | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3800641 %) | Approved, Investigational | 27742486 |
DrugRepV_2813 | Rizatriptan Benzoate | NA | Migraine disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.3908172 %) | Approved | 27742486 |
DrugRepV_2814 | 2-Thiouracil | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4015713 %) | NA | 27742486 |
DrugRepV_2815 | Naloxone Hydrochloride | Alimentary Tract And Metabolism; Various | Narcotic depression | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4307358 %) | Approved, Vet approved | 27742486 |
DrugRepV_2816 | Clofarabine | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4343488 %) | Approved | 27742486 |
DrugRepV_2817 | Pimecrolimus | Dermatologicals | Atopic dermatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4573493 %) | Approved, Investigational | 27742486 |
DrugRepV_2818 | Suplatast tosylate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.4609451 %) | NA | 27742486 |
DrugRepV_2819 | Vitamin C | Alimentary Tract and Metabolism | Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.5679794 %) | Approved | 27742486 |
DrugRepV_2820 | Oxcarbazepine | Nervous System | Partial seizures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.5907524 %) | Approved | 27742486 |
DrugRepV_2821 | Pramipexole Dihydrochloride Monohydrate | Nervous System | Parkinson's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.5989777 %) | Approved, Investigational | 27742486 |
DrugRepV_2822 | Naphazoline Hydrochloride | Respiratory System; Sensory Organ | Eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.636873 %) | Approved, Investigational | 27742486 |
DrugRepV_2823 | Nifedipine | Cardiovascular agents | Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.6404656 %) | Approved | 27742486 |
DrugRepV_2824 | Cabazitaxel | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.6935891 %) | Approved | 27742486 |
DrugRepV_2825 | Nystatin | Alimentary Tract And Metabolism; Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.7305272 %) | Approved | 27742486 |
DrugRepV_2826 | Medetomidine Hydrochloride | Nervous System | Surgical anesthetic | Analgesic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.7627474 %) | Approved, Vet approved | 27742486 |
DrugRepV_2827 | Acetylcysteine | Respiratory System; Sensory Organ; Various | Acetaminophen poisoning | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.8964245 %) | Approved | 27742486 |
DrugRepV_2828 | Paroxetine Hydrochloride | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9168009 %) | Approved, Investigational | 27742486 |
DrugRepV_2829 | Mesna | Respiratory System; Various | Hemorrhagic cystitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9168504 %) | Approved, Investigational | 27742486 |
DrugRepV_2830 | Idebenone | Nervous System | Visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.92252 %) | Approved, Investigational | 27742486 |
DrugRepV_2831 | Xylazine Hydrochloride | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9275587 %) | Approved, Vet Approved | 27742486 |
DrugRepV_2832 | Ornidazole | Antiparasitic products, Insectisides and Repellents | Elective Colorectal Surgery | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9457143 %) | Investigational | 27742486 |
DrugRepV_2833 | Etravirine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.947872 %) | Approved | 27742486 |
DrugRepV_2834 | Evista | Genito Urinary System and Sex Hormones | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-5.9810114 %) | Approved | 27742486 |
DrugRepV_2835 | Tadalafil | Genito Urinary System and Sex Hormones | Erectile dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.0935254 %) | Approved | 27742486 |
DrugRepV_2836 | Ezetimibe | Cardiovascular agents | Hyperlipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.124775 %) | Approved | 27742486 |
DrugRepV_2837 | Pazopanib | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2172761 %) | Approved | 27742486 |
DrugRepV_2838 | Romidepsin | Antineoplastic and Immunomodulating Agents | T-cell lymphoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2173849 %) | Approved, Investigational | 27742486 |
DrugRepV_2839 | Emtricitabine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2439742 %) | Approved | 27742486 |
DrugRepV_2840 | Valsartan | Cardiovascular agents | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.2598292 %) | Approved | 27742486 |
DrugRepV_2841 | Venlafaxine | Nervous System | Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3017038 %) | Approved | 27742486 |
DrugRepV_2842 | Abitrexate | Antineoplastic and Immunomodulating Agents | Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3272062 %) | Approved | 27742486 |
DrugRepV_2843 | Danofloxacin Mesylate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3487008 %) | Experimental, Vet approved | 27742486 |
DrugRepV_2844 | Eplerenone | Cardiovascular agents | Left ventricular systolic dysfunction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.3670777 %) | Approved | 27742486 |
DrugRepV_2845 | Atracurium Besylate | Musculo-Skeletal System | Endotracheal intubation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.50194 %) | Approved | 27742486 |
DrugRepV_2846 | Divalproex Sodium | Nervous System | Seizures | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.5343075 %) | Approved | 27742486 |
DrugRepV_2847 | Topiramate | Nervous System | Seizures (Epilepsy) | Migraine | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.553453 %) | Approved | 27742486 |
DrugRepV_2848 | Glipizide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.5735462 %) | Approved, Investigational | 27742486 |
DrugRepV_2849 | Amikacin Sulfate | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.6506378 %) | Approved | 27742486 |
DrugRepV_2850 | Palonosetron Hydrochloride | Alimentary Tract and Metabolism | Nausea and vomiting associated with cancer chemotherapy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.7579581 %) | Approved, Investigational | 27742486 |
DrugRepV_2851 | Sulfamethoxazole | Antiinfectives For Systemic Use | Bacterial infections (Bronchitis, prostatitis and urinary tract infections) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.7837639 %) | Approved | 27742486 |
DrugRepV_2852 | Vildagliptin | Alimentary Tract and Metabolism | Hyperglycemia in type 2 diabetes mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8331475 %) | Approved | 27742486 |
DrugRepV_2853 | Rimonabant | Alimentary Tract and Metabolism | Obesity | Type 2 diabetes or dyslipidaemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8569753 %) | Approved, Investigational | 27742486 |
DrugRepV_2854 | Prednisolone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.875743 %) | Approved, Vet approved | 27742486 |
DrugRepV_2855 | Betamethasone Dipropionate | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Edocrine disorders, rheumatic disorders, collagen diseases | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8812088 %) | Approved | 27742486 |
DrugRepV_2856 | Amidopyrine | NA | Pain | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8828073 %) | NA | 27742486 |
DrugRepV_2857 | Rolipram | Antidepressant | Depressive disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-6.8983502 %) | Approved | 27742486 |
DrugRepV_2858 | Zolmitriptan | Nervous System | Migraine with or without auras | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.0517546 %) | Approved | 27742486 |
DrugRepV_2859 | Ciclopirox ethanolamine | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.0876735 %) | Approved | 27742486 |
DrugRepV_2860 | Clotrimazole | Dermatologicals | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.1110368 %) | Approved | 27742486 |
DrugRepV_2861 | Ubenimex | NA | Acute myelocytic leukemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.1327673 %) | Approved | 27742486 |
DrugRepV_2862 | Estradiol | Genito Urinary System and Sex Hormones | Vulvar and vaginal atrophy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2174786 %) | Approved | 27742486 |
DrugRepV_2863 | Pitavastatin Calcium | Cardiovascular agents | Dyslipidemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2349302 %) | Approved | 27742486 |
DrugRepV_2864 | Epirubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2856781 %) | Approved | 27742486 |
DrugRepV_2865 | Solifenacin Succinate | Genito Urinary System and Sex Hormones | Overactive bladder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.2907234 %) | Approved | 27742486 |
DrugRepV_2866 | Carbazochrome Sodium Sulfonate | Blood and Blood Forming Organs | Hemorrhage | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3048436 %) | Experimental | 27742486 |
DrugRepV_2867 | Fexofenadine Hydrochloride | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3594321 %) | Approved | 27742486 |
DrugRepV_2868 | Furosemide | Cardiovascular agents | Edema and Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3838268 %) | Approved, Vet approved | 27742486 |
DrugRepV_2869 | Enrofloxacin | Antibiotics | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.5865927 %) | NA | 27742486 |
DrugRepV_2870 | Alverine Citrate | Alimentary Tract and Metabolism | Muscle spasms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.6069373 %) | Approved | 27742486 |
DrugRepV_2871 | Daunorubicin Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.6172048 %) | Approved | 27742486 |
DrugRepV_2872 | Tolvaptan | Cardiovascular agents | Hyponatremia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.7162491 %) | Approved | 27742486 |
DrugRepV_2873 | Acitretin | Dermatologicals | Psoriasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.7772745 %) | Approved | 27742486 |
DrugRepV_2874 | Allopurinol | Musculo-Skeletal System | Hyperuricemia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.0088421 %) | Approved | 27742486 |
DrugRepV_2875 | Peramivir Trihydrate | Antiviral | Influenza A/B virus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.0856963 %) | Approved | 27742486 |
DrugRepV_2876 | Blonanserin | Neurologic-agent | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.1057248 %) | Investigational | 27742486 |
DrugRepV_2877 | Fenoprofen Calcium Hydrate | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.1318763 %) | Approved | 27742486 |
DrugRepV_2878 | Betapar | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.1507562 %) | NA | 27742486 |
DrugRepV_2879 | Indomethacin | Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System | Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.1963187 %) | Approved, Investigational | 27742486 |
DrugRepV_2880 | Hydrochlorothiazide | Cardiovascular agents | High blood pressure | Edema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2049254 %) | Approved, Vet approved | 27742486 |
DrugRepV_2881 | Doxorubicin | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2310876 %) | Approved | 27742486 |
DrugRepV_2882 | Tolnaftate | Dermatologicals | Skin infections (Fungal) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.2646691 %) | Approved | 27742486 |
DrugRepV_2883 | Desonide | Dermatologicals | Inflammatory disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.3310624 %) | Approved | 27742486 |
DrugRepV_2884 | Aspirin | Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Nervous System | Rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.3358431 %) | Approved | 27742486 |
DrugRepV_2885 | Carvedilol | Cardiovascular agents | Congestive heart failure | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.3562769 %) | Approved | 27742486 |
DrugRepV_2886 | Stavudine | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.4649195 %) | Approved, Investigational | 27742486 |
DrugRepV_2887 | Melatonin | Nervous System | Jet lag | Insomnia | Shift-work disorder | Circadian rhythm disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.4723795 %) | Approved, Nutraceutical, Vet approved | 27742486 |
DrugRepV_2888 | Cinepazide Maleate | Cardiovascular agents | Ischemic Stroke | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.5219495 %) | Investigational | 27742486 |
DrugRepV_2889 | Malotilate | NA | Liver disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.5901104 %) | NA | 27742486 |
DrugRepV_2890 | Levodopa | Nervous System | Parkinson's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.6262322 %) | Approved | 27742486 |
DrugRepV_2891 | PMSF | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.6777643 %) | NA | 27742486 |
DrugRepV_2892 | Sparfloxacin | Antiinfectives For Systemic Use | Pneumonia | Acute bacterial exacerbations of chronic bronchitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.7240967 %) | Approved, Investigational, Withdrawn | 27742486 |
DrugRepV_2893 | Lurasidone Hydrochloride | Nervous System | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.7511975 %) | Approved, Investigational | 27742486 |
DrugRepV_2894 | Bindarit | Anti-diabetic | Coronary Restenosis and Diabetic Nephropathy | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.7514692 %) | Investigational | 27742486 |
DrugRepV_2895 | Moclobemide | Nervous System | Depressive disorder | Bipolar disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-8.9210779 %) | Approved, Investigational | 27742486 |
DrugRepV_2896 | Methimazole | Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins | Hyperthyroidism | Goiter | Graves disease | Psoriasis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.0110469 %) | Approved | 27742486 |
DrugRepV_2897 | Mosapride Citrate | Gastroprokinetic agent | Postoperative Ileus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.0916916 %) | Investigational | 27742486 |
DrugRepV_2898 | Ketoprofen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.0969554 %) | Approved, Vet approved | 27742486 |
DrugRepV_2899 | Bufexamac | Musculo-Skeletal System | Eczema and dermatoses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.1032426 %) | Approved | 27742486 |
DrugRepV_2900 | Hydrocortisone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Dermatoses | Immune and allergic disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.1034782 %) | Approved, Vet approved | 27742486 |
DrugRepV_2901 | Amoxicillin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.1354562 %) | Approved | 27742486 |
DrugRepV_2902 | Cefdinir | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.1747501 %) | Approved | 27742486 |
DrugRepV_2903 | Lamotrigine | Nervous System | Epilepsy and bipolar disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.203636 %) | Approved, Investigational | 27742486 |
DrugRepV_2904 | Ethisterone | Genito Urinary System and Sex Hormones | Gynecological disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.2262254 %) | NA | 27742486 |
DrugRepV_2905 | Rofecoxib | Musculo-Skeletal System | Osteoarthritis | Rheumatoid arthritis | Acute pain in adults | Primary dysmenorrhea | Acute treatment of migraine attacks with or without auras | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.4168988 %) | Approved | 27742486 |
DrugRepV_2906 | Sulfathiazole | Dermatologicals; Antiinfectives For Systemic Use | Bacterial infections (Cattle) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.4569269 %) | Approved, Vet approved | 27742486 |
DrugRepV_2907 | Tranilast | NA | Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.5539143 %) | Investigational | 27742486 |
DrugRepV_2908 | Aminocaproic Acid | Blood and Blood Forming Organs | Antifibrinolytic agent | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.6373425 %) | Approved | 27742486 |
DrugRepV_2909 | Estrone | Genito Urinary System and Sex Hormones | Perimenopausal and postmenopausal symptoms | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.6830838 %) | Approved | 27742486 |
DrugRepV_2910 | Orlistat | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.7414562 %) | Approved, Investigational | 27742486 |
DrugRepV_2911 | Sulfanilamide | Antiinfectives For Systemic Use | Vulvovaginitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.7841731 %) | Approved | 27742486 |
DrugRepV_2912 | Prednisone | Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.8505525 %) | Approved, Vet approved | 27742486 |
DrugRepV_2913 | Noradrenaline Bitartrate Monohydrate | NA | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-9.8741533 %) | NA | 27742486 |
DrugRepV_2914 | Pramipexole | Nervous System | Parkinson's disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.257475 %) | Approved, Investigational | 27742486 |
DrugRepV_2915 | Glyburide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.433422 %) | Approved | 27742486 |
DrugRepV_2916 | Chlorothiazide | Cardiovascular agents | Edema associated with congestive heart failure, hepatic cirrhosis and hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.451156 %) | Approved | 27742486 |
DrugRepV_2917 | Terbinafine | Dermatologicals | Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.718001 %) | Approved, Investigational, Vet approved | 27742486 |
DrugRepV_2918 | Tioconazole | Dermatologicals; Genito Urinary System and Sex Hormones | Vulvovaginal candidiasis (moniliasis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-10.954794 %) | Approved | 27742486 |
DrugRepV_2919 | Doxifluridine | Anticancer | Stomach cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.000576 %) | Investigational | 27742486 |
DrugRepV_2920 | Fenticonazole nitrate | Dermatologicals | Fungal infections (Vulvovaginal candidiasis) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.000576 %) | Experimental | 27742486 |
DrugRepV_2921 | Busulfan | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.084498 %) | Approved | 27742486 |
DrugRepV_2922 | Amphotericin B | Antiinfectives For Systemic Use | Fungal infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.133117 %) | Approved | 27742486 |
DrugRepV_2923 | Phenylbutazone | Musculo-Skeletal System | Backache | Ankylosing spondylitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.578798 %) | Approved, Vet approved | 27742486 |
DrugRepV_2924 | Trifluoperazine Dihydrochloride | Nervous System | Schizophrenia and other psychotic disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.74809 %) | Approved | 27742486 |
DrugRepV_2925 | Ibuprofen | Musculo-Skeletal System | Rheumatoid arthritis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.93197 %) | Approved | 27742486 |
DrugRepV_2926 | Alendronate | Musculo-Skeletal System | Paget disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.958789 %) | Approved | 27742486 |
DrugRepV_2927 | Amiodarone Hydrochloride | Cardiovascular agents | Anginal and Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.235293 %) | Approved | 27742486 |
DrugRepV_2928 | Paliperidone | Nervous System | Schizophrenia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.545451 %) | Approved | 27742486 |
DrugRepV_2929 | Biperiden Hydrochloride | Nervous System | Parkinson disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.770433 %) | Approved | 27742486 |
DrugRepV_2930 | Nilvadipine | Cardiovascular agents | Angina | Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.889881 %) | Approved | 27742486 |
DrugRepV_2931 | Adenosine | Cardiovascular agents | Arrhythmia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-12.932123 %) | Approved | 27742486 |
DrugRepV_2932 | Riluzole | Nervous System | Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-13.776241 %) | Approved, Investigational | 27742486 |
DrugRepV_2933 | Erythromycin | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-14.433754 %) | Approved | 27742486 |
DrugRepV_2934 | Chloramphenicol | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-14.926902 %) | Approved | 27742486 |
DrugRepV_2935 | Monobenzone | Dermatologicals | Vitiligo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-16.860885 %) | Approved | 27742486 |